Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 3.2.1.20 - alpha-glucosidase

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Abscess
Measurement of alpha-glucosidase activity in serum from patients with cystic fibrosis or pancreatitis.
Acidosis
Rumen microbial and fermentation characteristics are affected differently by acarbose addition during two nutritional types of simulated severe subacute ruminal acidosis in vitro.
Acidosis, Lactic
Oral antidiabetic agents. The emergence of alpha-glucosidase inhibitors.
Potential of alpha-glucosidase inhibitors in elderly patients with diabetes mellitus and impaired glucose tolerance.
Acquired Immunodeficiency Syndrome
Prenatal diagnosis of cystic fibrosis by assay of amniotic fluid microvillar enzymes.
Acute Kidney Injury
Acute renal failure related to intravenous immunoglobulin infusion in an elderly woman.
[Functional recovery phase of acute renal insufficiency. Behavior and significance of urinary excretion of alpha-glucosidase, gamma-glutamyltransferase, lysozyme and beta 2 microglobulin]
Adenocarcinoma
The cation-independent mannose 6-phosphate receptor is not involved in the polarized secretion of lysosomal alpha-glucosidase from Caco-2 cells.
Adenoma
Neoplasia and hyperplasia of large bowel: focal lesions in an abnormal epithelium.
alpha-galactosidase deficiency
[Clinical, preclinical and prenatal diagnosis of congenital sphingolipidoses by determining lysosomal hydrolases (author's transl)]
alpha-glucosidase deficiency
Abnormal trafficking of sarcolemmal proteins in alpha-glucosidase deficiency.
alpha-Glucosidase deficiency (Pompe's disease).
Alpha-glucosidase deficiency and basilar artery aneurysm: report of a sibship.
Alpha-glucosidase deficiency in a child.
alpha-Glucosidase deficiency in generalized glycogenstorage disease (Pompe's disease).
Biopsy-proven alpha-glucosidase deficiency with normal lymphocyte enzyme activity.
Broad spectrum of Pompe disease in patients with the same c.-32-13T->G haplotype.
Canine glycogen storage disease type II. A biochemical study of an acid alpha-glucosidase-deficient Lapland dog.
Characterization of intestinal gamma-glucoamylase deficiency in CBA/Ca mice.
Clinical Characteristics of Disaccharidase Deficiencies Among Children Undergoing Upper Endoscopy.
Clinical manifestation and natural course of late-onset Pompe's disease in 54 Dutch patients.
Comparative pathology of the canine model of glycogen storage disease type II (Pompe's disease).
Cystic fibrosis newborn screening: a model for neuromuscular disease screening?
Detection of human acid alpha-glucosidase in fibroblasts using monoclonal antibodies in a biotin-avidin amplified ELISA.
Diagnosis of Pompe disease: muscle biopsy vs blood-based assays.
Disaccharidase activity in children undergoing esophagogastroduodenoscopy: A systematic review.
Effect of enzyme replacement therapy (ERT) added to Home Mechanical Ventilation (HMV) in Adult Pompe disease.
Enzyme replacement therapy for infantile Pompe disease during the critical period and identification of a novel mutation.
Extended phenotype description and new molecular findings in late onset glycogen storage disease type II: a northern Italy population study and review of the literature.
Glycogen storage disease type II in Israel.
Improvement of dysphagia in a child affected by Pompe disease treated with enzyme replacement therapy.
Late-Onset Glycogen Storage Disease Type II (Pompe's Disease) with a Novel Mutation: A Malaysian Experience.
Metabolic Impacts of Maltase Deficiencies.
Patients with functional bowel disorder have disaccharidase deficiency: A single-center study from Russia.
Prenatal diagnosis of Pompe disease by electron microscopy.
Prenatal exclusion of Pompe disease by electron microscopy.
Preparation of monoclonal antibodies against acid alpha-D-glucosidase for study of Chinese glycogenosis type II patients.
Screening for Pompe disease using a rapid dried blood spot method: experience of a clinical diagnostic laboratory.
Selective alteration of brush-border hydrolases in intestinal diseases in childhood.
Selective lactase deficiency is common in pediatric patients undergoing upper endoscopy.
Selective vacuolar myopathy with atrophy of type II fibers. Occurrence in a childhood case of acid maltase deficiency.
Sleep-related obstructive and nonobstructive apneas and neurologic disorders.
Small intestinal glucoamylase deficiency and starch malabsorption: a newly recognized alpha-glucosidase deficiency in children.
The role of probiotic cultures in the control of gastrointestinal health.
Vacuolar myopathy with type 2 A fiber atrophy and type 2 B fiber deficiency. A case of childhood form acid alpha-1,4-glucosidase deficiency.
White blood cells and the diagnosis of alpha-glucosidase deficiency.
[Disaccharidase deficiency and functional bowel diseases].
[Heterogeneity of glycogenosis with alpha-1,4-glucosidase deficiency: enzymatic studies in three families (author's transl)]
[Ichthyosiform scaling in alpha-1,4-glucosidase deficiency]
[Muscular glycogenosis caused by alpha-1,4-glucosidase deficiency simulating progressive muscular dystrophy. (Clinical and enzyme study. Optic and electron microscopy)]
[Pseudodystrophic muscle glycogenosis in adults. (Acid maltase deficiency syndrome) (author's transl)]
Anaphylaxis
Desensitization of an adult patient with Pompe disease and a history of anaphylaxis to alglucosidase alfa.
Aneurysm
Alpha-glucosidase deficiency and basilar artery aneurysm: report of a sibship.
Arthritis
Inhibition of adjuvant arthritis in the rat by phosphosugars and the alpha-glucosidase inhibitor castanospermine.
[Activity of acid hydrolases in rat tissues under experimental arthritis]
Arthritis, Experimental
Alpha-Glucosidase Inhibitors Alter Gut Microbiota and Ameliorate Collagen-Induced Arthritis.
Inhibition of adjuvant arthritis in the rat by phosphosugars and the alpha-glucosidase inhibitor castanospermine.
[Activity of acid hydrolases in rat tissues under experimental arthritis]
arylsulfatase (type i) deficiency
[Clinical, preclinical and prenatal diagnosis of congenital sphingolipidoses by determining lysosomal hydrolases (author's transl)]
Asthenozoospermia
Epididymal secretory function in men with asthenoteratozoospermia.
New discriminatory level for glucosidase activity to diagnose epididymal obstruction or dysfunction.
Asthma
Serum neutral alpha-D-glucosidase from patients with cystic fibrosis and chronic pulmonary disease.
Astrocytoma
Activity of glycogen depolymerizing enzymes in extracts from brain tumor tissue (anaplastic astrocytoma and glioblastoma multiforme).
Atherosclerosis
alpha-Glucosidase inhibitor reduces the progression of carotid intima-media thickness.
In vitro inhibitory effects of Limonium contortirameum and L. virgatum extracts from sardinia on alpha-amylase, alpha-glucosidase and pancreatic lipase.
Swings in blood glucose levels accelerate atherogenesis in apolipoprotein E-deficient mice.
Azoospermia
Alpha-1,4-glucosidase activity and the presence of germinal epithelium cells in the semen for differential diagnosis of obstructive and nonobstructive azoospermia.
Alpha-glucosidase as a specific epididymal enzyme marker. Its validity for the etiologic diagnosis of azoospermia.
Clinical experience with azoospermia: aetiology and chances for spermatozoa detection upon biopsy.
Enzymes in the seminal plasma from azoospermic men: correlation with the origin of their azoospermia.
Improvement in the assessment of human epididymal function by the use of inhibitors in the assay of alpha-glucosidase in seminal plasma.
Neutral alpha-1,4-glucosidase and fructose levels contribute to discriminating obstructive and nonobstructive azoospermia in Chinese men with azoospermia.
New discriminatory level for glucosidase activity to diagnose epididymal obstruction or dysfunction.
Origin of maltase and variations in infertile men.
Relationship between lipocalin-type prostaglandin D synthase and alpha-glucosidase in azoospermia seminal plasma.
Relationship between semen quality and the seminal plasma components carnitine, alpha-glucosidase, fructose, citrate and granulocyte elastase in infertile men compared with a normal population.
Screening for obstruction of the vas deferens in Nigerian men with azoospermia using the alpha-glucosidase reaction in semen.
Simultaneous measurement of seminal L-carnitine, alpha,1-4-glucosidase, and glycerylphosphorylcholine in azoospermic and oligozoospermic patients.
[Analysis of the relative etiology of non-obstructive azoospermia]
[Neutral alpha-glucosidase activity is correlated with the location of epididymal obstruction in azoospermia men].
[Surgical treatment of obstructive azoospermia: a report of 56 cases]
beta-fructofuranosidase deficiency
Clinical Characteristics of Disaccharidase Deficiencies Among Children Undergoing Upper Endoscopy.
Disaccharidase activity in children undergoing esophagogastroduodenoscopy: A systematic review.
Interaction between dietary carbohydrates and intestinal disaccharidases in experimental diarrhea.
Patients with functional bowel disorder have disaccharidase deficiency: A single-center study from Russia.
beta-glucosidase deficiency
[Clinical, preclinical and prenatal diagnosis of congenital sphingolipidoses by determining lysosomal hydrolases (author's transl)]
Breast Neoplasms
Differential proteome analysis of replicative senescence in rat embryo fibroblasts.
Serum beta-N-acetylglucosaminidase, beta-D-glucosidase, alpha-D-glucosidase, beta-D-fucosidase, alpha-L-fucosidase and beta-D-galactosidase levels in acute viral hepatitis, pancreatitis, myocardial infarction and breast cancer.
Carcinoma
Neoplasia and hyperplasia of large bowel: focal lesions in an abnormal epithelium.
New antihyperglycemic, alpha-glucosidase inhibitory, and cytotoxic derivatives of benzimidazoles.
Carcinoma, Hepatocellular
Alpha-glucosidase activity in reference to glycogen storage, and formation of glycogenosomes in ascites hepatoma AH13 cells. Comparison of AH13 cells with ascites hepatoma AH109A and normal liver.
Antiviral effect of {alpha}-glucosidase inhibitors on viral morphogenesis and binding properties of hepatitis C virus-like particles.
Biochemical microanalysis of alpha-glucosidase activity in preneoplastic and neoplastic hepatic lesions induced in rats by N-nitrosomorpholine.
Serum and host liver activities of glycosidases and sialyltransferases in animals bearing transplantable tumors.
Thiazolidinediones, alpha-glucosidase inhibitors, meglitinides, sulfonylureas, and hepatocellular carcinoma risk: A meta-analysis.
Cardiomegaly
Long-term follow-up results in enzyme replacement therapy for Pompe disease: a case report.
Cardiomyopathies
A review of treatment of Pompe disease in infants.
Antisense Oligonucleotide-mediated Suppression of Muscle Glycogen Synthase 1 Synthesis as an Approach for Substrate Reduction Therapy of Pompe Disease.
Cardiac responses in paediatric Pompe disease in the ADVANCE patient cohort.
Enhanced response to enzyme replacement therapy in pompe disease after the induction of immune tolerance.
Enzyme replacement therapy for infantile-onset Pompe disease.
Fractures in children with Pompe disease: a potential long-term complication.
Glycogen storage disease types I and II: treatment updates.
High dose IVIG successfully reduces high rhGAA IgG antibody titers in a CRIM-negative infantile Pompe disease patient.
Long-term enzyme replacement therapy for pompe disease with recombinant human alpha-glucosidase derived from chinese hamster ovary cells.
New therapeutic approaches for Pompe disease: enzyme replacement therapy and beyond.
Postmortem Findings and Clinical Correlates in Individuals with Infantile-Onset Pompe Disease.
Recombinant human alpha-glucosidase from rabbit milk in Pompe patients.
[Cardiomuscular lysosomal glycogenosis in adults without known enzyme deficiency. A cause of familial myocardiopathy and lysosomal glycogen overload with normal acid maltase]
Cardiovascular Diseases
Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial.
Acarbose, an alpha-glucosidase inhibitor, decreases aortic gene expression and serum levels of monocyte chemoattractant protein-1 in fructose-fed rats.
Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose.
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2016 EXECUTIVE SUMMARY.
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2017 EXECUTIVE SUMMARY.
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2018 EXECUTIVE SUMMARY.
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2019 EXECUTIVE SUMMARY.
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2020 EXECUTIVE SUMMARY.
Inhibitory effects of estrogens on digestive enzymes, insulin deficiency, and pancreas toxicity in diabetic rats.
Miglitol improves postprandial endothelial dysfunction in patients with acute coronary syndrome and new-onset postprandial hyperglycemia.
Single administration of alpha-glucosidase inhibitors on endothelial function and incretin secretion in diabetic patients with coronary artery disease - Juntendo University trial: effects of miglitol on endothelial vascular reactivity in type 2 diabetic patients with coronary heart disease (J-MACH) -.
Systemic medications and cortical cataract: the Singapore Epidemiology of Eye Diseases Study.
[The clinical significance of early intervention for impaired glucose tolerance]
Cataract
Systemic medications and cortical cataract: the Singapore Epidemiology of Eye Diseases Study.
Celiac Disease
Review: Management of postprandial diarrhea syndrome.
[Carbohydrase activities may serve as a marker for small intestinal mucosal recovery in patients with celiac disease].
Cholestasis
Influence of biliary stasis on the activity and distribution of maltase, sucrase, alkaline phosphatase, and leucylnaphthylamidase in the small intestine of the mouse.
Cholestasis, Extrahepatic
Activity of alpha-1,4-glucosidase in extrahepatic cholestasis and acute viral hepatitis.
Cholestasis, Intrahepatic
[The influences of endogenous bile acids on maltase and alkaline phosphatase activities in intrahepatic cholestasis rats]
Colonic Neoplasms
Effects of acetaldehyde on brush border enzyme activities in human colon adenocarcinoma cell line Caco-2.
Lysosomal alpha-glucosidase: cell-specific processing and altered maturation in HT-29 colon cancer cells.
Communicable Diseases
Mineral Analysis, In Vitro Evaluation of Alpha-Amylase, Alpha-Glucosidase, and Beta-Galactosidase Inhibition, and Antibacterial Activities of Juglans regia L. Bark Extracts.
Coronary Artery Disease
Single administration of alpha-glucosidase inhibitors on endothelial function and incretin secretion in diabetic patients with coronary artery disease - Juntendo University trial: effects of miglitol on endothelial vascular reactivity in type 2 diabetic patients with coronary heart disease (J-MACH) -.
Coronary Disease
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2016 EXECUTIVE SUMMARY.
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2017 EXECUTIVE SUMMARY.
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2018 EXECUTIVE SUMMARY.
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2019 EXECUTIVE SUMMARY.
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2020 EXECUTIVE SUMMARY.
Single administration of alpha-glucosidase inhibitors on endothelial function and incretin secretion in diabetic patients with coronary artery disease - Juntendo University trial: effects of miglitol on endothelial vascular reactivity in type 2 diabetic patients with coronary heart disease (J-MACH) -.
Cystic Fibrosis
Acid hydrolases in sera and plasma from patients with cystic fibrosis.
Activity levels and properties of acid alpha-glucosidase from liver and neutral alpha-glucosidase from sera of cystic fibrosis patients and controls.
Alpha-glucosidase in cystic fibrosis.
Characteristics of maltase activity in amniotic fluid.
Disaccharidase deficiency in amniotic fluid from cases of cystic fibrosis.
Enzyme analysis of amniotic fluid for prenatal diagnosis of cystic fibrosis in high-risk pregnancies.
Glycosidases in serum of cystic fibrosis patients.
Measurement of alpha-glucosidase activity in serum from patients with cystic fibrosis or pancreatitis.
Prenatal detection of cystic fibrosis; comparative study of maltase and alkaline phosphatase activities in amniotic fluid.
Prenatal diagnosis of cystic fibrosis by assay of amniotic fluid microvillar enzymes.
Rescue of functional delF508-CFTR channels in cystic fibrosis epithelial cells by the alpha-glucosidase inhibitor miglustat.
Seminal plasma characteristics as indicators of cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations in men with obstructive azoospermia.
Serum neutral alpha-D-glucosidase from patients with cystic fibrosis and chronic pulmonary disease.
Small intestinal brush border enzymes in cystic fibrosis.
Studies in meconium: disaccharidase activities in meconium from cystic fibrosis patients and controls.
Cysts
Intestinal alpha-glucosidase inhibitors: abdominal gas cysts.
Deglutition Disorders
Improvement of dysphagia in a child affected by Pompe disease treated with enzyme replacement therapy.
Dementia
Loss of endoplasmic reticulum-associated enzymes in affected brain regions in Huntington's disease and Alzheimer-type dementia.
Dengue
Alpha-glucosidase inhibitors reduce dengue virus production by affecting the initial steps of virion morphogenesis in the endoplasmic reticulum.
Castanospermine, a potent inhibitor of dengue virus infection in vitro and in vivo.
Dental Caries
Partial purification and characterization of alpha-glucosidase from Rothia dentocariosa.
Dental Plaque
Effect of the alpha-glucosidase inhibitor, acarbose, on disaccharide splitting enzymes in human dental plaque.
Sucrase and maltase activities in supragingival dental plaque in humans of streptococcal, actinomyces and lactobacilli species.
Dermatomyositis
Additive contribution of multiple factors in the development of pneumatosis intestinalis: a case report and review of the literature.
Diabetes Complications
Combination of oral antidiabetic drugs and insulin in the treatment of non-insulin-dependent diabetes.
Repetitive postprandial hyperglycemia increases cardiac ischemia/reperfusion injury: prevention by the alpha-glucosidase inhibitor acarbose.
The mechanism of alpha-glucosidase inhibition in the management of diabetes.
[Development of alpha-glucosidase inhibitor from medicinal herbs]
Diabetes Mellitus
A cardiologic approach to non-insulin antidiabetic pharmacotherapy in patients with heart disease.
A series of cinnamic acid derivatives and their inhibitory activity on intestinal alpha-glucosidase.
Acarbose related diarrhea: increased butyrate upregulates prostaglandin E.
Acarbose: its role in the treatment of diabetes mellitus.
Advantages of alpha-glucosidase inhibition as monotherapy in elderly type 2 diabetic patients.
alpha-Glucosidase and alpha-amylase inhibitory activities of saponins from traditional Chinese medicines in the treatment of diabetes mellitus.
alpha-Glucosidase inhibition in the treatment of diabetes mellitus.
Alpha-glucosidase inhibitor use is associated with decreased colorectal neoplasia risk in patients with type 2 diabetes mellitus receiving colonoscopy: a retrospective study.
Alpha-glucosidase inhibitors and risk of cancer in patients with diabetes mellitus: a systematic review and meta-analysis.
Alpha-glucosidase inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type 2 diabetes mellitus.
Alpha-glucosidase inhibitors for type 2 diabetes mellitus.
Alpha-glucosidase inhibitory activity and lipid-lowering mechanisms of Moringa oleifera leaf extract.
Amelioration of Diabetes mellitus by modulation of GLP-1 via targeting alpha-glucosidase using Acacia tortilis polysaccharide in Streptozotocin-Nicotinamide induced diabetes in rats.
An ?-glucosidase inhibitor could reduce T-wave alternans in type 2 diabetes patients.
An evaluation of the potential side-effects of alpha-glucosidase inhibitors used for the management of diabetes mellitus.
Association between ?-glucosidase inhibitor use and psoriatic disease risk in patients with type 2 diabetes mellitus: A population-based cohort study.
Changes in alpha-glucosidase activities along the jejunal-ileal axis of normal rats by the alpha-glucosidase inhibitor miglitol.
Clinical effect of combination therapy of pioglitazone and an alpha-glucosidase inhibitor.
Clinical inquiries. What is the best medical therapy for new-onset type 2 diabetes?
Comparative RNA-sequencing of the acarbose producer Actinoplanes sp. SE50/110 cultivated in different growth media.
Comparison of the effect of glucose-lowering agents on the risk of atrial fibrillation: A network meta-analysis.
Complete genome sequence of the actinobacterium Streptomyces glaucescens GLA.O (DSM 40922) consisting of a linear chromosome and one linear plasmid.
Diabetes mellitus secondary to glycogen storage disease type III.
Do Alpha-glucosidase Inhibitors Have the Potential to Induce Portal Venous Gas? -Two Clinical Case Reports.
Dose-dependent efficacy of miglitol, an alpha-glucosidase inhibitor, in type 2 diabetic patients on diet alone: results of a 24-week double-blind placebo-controlled study.
Effect of a new hypoglycemic agent, A-4166 [(-)-N-(trans-4-isopropylcyclohexanecarbonyl)-D-phenylalanine], on postprandial blood glucose excursion: comparison with voglibose and glibenclamide.
Effect of acarbose on postprandial lipid metabolism in type 2 diabetes mellitus.
Effect of acarbose, an alpha-glucosidase inhibitor, on serum lipoprotein lipase mass levels and common carotid artery intima-media thickness in type 2 diabetes mellitus treated by sulfonylurea.
Effect of an alpha-glucosidase inhibitor (BAY m 1099) on post-prandial blood glucose and insulin in type II diabetics.
Effect of Ca(2+) on the activity and structure of ?-glucosidase: Inhibition kinetics and molecular dynamics simulations.
Effect of inhibition of alpha-glucosidase on age-related glucose intolerance and pancreatic atrophy in rats.
Effect of pioglitazone on muscle sympathetic nerve activity in type 2 diabetes mellitus with alpha-glucosidase inhibitor.
Effect of the alpha-glucosidase inhibitor acarbose on control of glycemia in dogs with naturally acquired diabetes mellitus.
Effects of 8-wk alpha-glucosidase inhibition on metabolic control, C-peptide secretion, hepatic glucose output, and peripheral insulin sensitivity in poorly controlled type II diabetic patients.
Effects of alpha-glucosidase inhibition on meal glucose tolerance and timing of insulin administration in patients with type I diabetes mellitus.
Effects of beano on the tolerability and pharmacodynamics of acarbose.
Effects of changeover from voglibose to acarbose on postprandial triglycerides in type 2 diabetes mellitus patients.
Effects of diabetes and hyperglycemia on disaccharidase activities in the rat.
Effects of L-malic Acid on alpha-glucosidase: inhibition kinetics and computational molecular dynamics simulations.
Efficacy of combined use of miglitol in Type 2 diabetes patients receiving insulin therapy-placebo-controlled double-blind comparative study.
Established therapies for diabetes mellitus.
Hypoglycemic and hypolipidemic effects of Saururus chinensis Baill in streptozotocin-induced diabetic rats.
Improving management of type 2 diabetes mellitus: 1. alpha-Glucosidase inhibitors.
Improving the genome annotation of the acarbose producer Actinoplanes sp. SE50/110 by sequencing enriched 5'-ends of primary transcripts.
In vitro alpha-glucosidase and alpha-amylase enzyme inhibitory effects of Andrographis paniculata extract and andrographolide.
Inhibition of alpha-glucosidase and amylase by luteolin, a flavonoid.
Inhibitory activity of Euonymus alatus against alpha-glucosidase in vitro and in vivo.
Inhibitory effect of Azadirachta indica A. juss leaf extract on the activities of alpha-amylase and alpha-glucosidase.
Inhibitory effect of phloroglucinol on ?-glucosidase: Kinetics and molecular dynamics simulation integration study.
Isolation and characterization of an iridoid, Arbortristoside-C from Nyctanthes arbor-tristis Linn., a potential drug candidate for diabetes targeting ?-glucosidase.
Long-term effectiveness of a new alpha-glucosidase inhibitor (BAY m1099-miglitol) in insulin-treated type 2 diabetes mellitus.
Long-term ingestion of a fermented soybean-derived Touchi-extract with alpha-glucosidase inhibitory activity is safe and effective in humans with borderline and mild type-2 diabetes.
Long-term treatment with acarbose for the treatment of reactive hypoglycemia.
Neuroprotective effects of Moringa oleifera: Bio-guided GC-MS identification of active compounds in diabetic neuropathic pain model.
Oral hypoglycemic agents: insulin secretagogues, alpha-glucosidase inhibitors and insulin sensitizers.
Pharmacologic management of the older patient with type 2 diabetes mellitus.
Pioglitazone produces rapid and persistent reduction of vascular inflammation in patients with hypertension and type 2 diabetes mellitus who are receiving angiotensin II receptor blockers.
Pneumatosis cystoides intestinalis after alpha-glucosidase inhibitor treatment in a patient with interstitial pneumonitis.
Pneumatosis cystoides intestinalis in neuropsychiatric systemic lupus erythematosus with diabetes mellitus: case report and literature review.
Pneumatosis cystoides intestinalis of the ascending colon related to acarbose treatment: a case report.
Potent alpha-glucosidase inhibitors purified from the red alga Grateloupia elliptica.
Potential of alpha-glucosidase inhibitors in elderly patients with diabetes mellitus and impaired glucose tolerance.
Safe and effective treatment of diabetes mellitus associated with chronic liver diseases with an alpha-glucosidase inhibitor, acarbose.
Structural and functional characterization of polyphenols isolated from acerola (Malpighia emarginata DC.) fruit.
Synergisms in Alpha-glucosidase Inhibition and Antioxidant Activity of Camellia sinensis L. Kuntze and Eugenia uniflora L. Ethanolic Extracts.
Synthesis of novel triterpene and N-allylated/N-alkylated niacin hybrids as ?-glucosidase inhibitors.
Synthesis, biological activity, and molecular modeling studies of 1H-1,2,3-triazole derivatives of carbohydrates as alpha-glucosidases inhibitors.
Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus.
The alpha-glucosidase inhibitor miglitol decreases glucose fluctuations and inflammatory cytokine gene expression in peripheral leukocytes of Japanese patients with type 2 diabetes mellitus.
The complete genome sequence of the acarbose producer Actinoplanes sp. SE50/110.
The effect of two new alpha-glucosidase inhibitors on metabolic responses to a mixed meal in normal volunteers.
The STOP-NIDDM Trial: an international study on the efficacy of an alpha-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data. Study to Prevent Non-Insulin-Dependent Diabetes Mellitus.
Treatment of feline diabetes mellitus using an alpha-glucosidase inhibitor and a low-carbohydrate diet.
Treatment of type 2 diabetes mellitus in children and adolescents.
Type 2 diabetes mellitus: what is the optimal treatment regimen?
Urinary excretion of beta-glucuronidase, N-acetyl-beta-D-glucosaminidase, alpha-glucosidase and trehalase in diabetes mellitus.
[Alpha-glucosidase inhibitor for the prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese subjects with impaired glucose tolerance]
[alpha-Glucosidase inhibitors in the therapy of diabetes mellitus]
[Alpha-glucosidase inhibitors: a new therapeutic approach in diabetes and functional hypoglycemia]
[Current status of the treatment of type 2 diabetes mellitus. Alpha-glucosidase inhibitors]
[Drug clinics. How I treat various metabolic diseases treated by a drug intervention that targets the intestine]
[Study on the inhibition of alpha-glucosidase by soyasaponins]
[The alpha-glucosidase inhibitor miglitol for the treatment of type 2 diabetes mellitus in the doctor's office]
[The use of the alpha-glucosidase inhibitor acarbose for the treatment of type-2 diabetes mellitus in secondary sulfanilamide resistance]
[Treatment of type 2 diabetes mellitus with the alpha-glucosidase inhibitor Miglitol in the doctor's office]
[Use of oral hypoglycemic agents in patients with chronic kidney failure.]
Diabetes Mellitus, Type 1
A new alpha-glucosidase inhibitor (Bay-m-1099) reduces insulin requirements with meals in insulin-dependent diabetes mellitus.
Alpha-glucosidase inhibition and timing of preprandial insulin in patients with insulin-dependent diabetes mellitus (IDDM).
Alpha-glucosidase inhibition as an adjunct to the treatment of type 1 diabetes.
alpha-Glucosidase inhibition improves postprandial hyperglycemia and decreases insulin requirements in insulin-dependent diabetes mellitus.
Alternative Agents in Type 1 Diabetes in Addition to Insulin Therapy: Metformin, Alpha-Glucosidase Inhibitors, Pioglitazone, GLP-1 Agonists, DPP-IV Inhibitors, and SGLT-2 Inhibitors.
Discovery of novel pyrido-pyrrolidine hybrid compounds as alpha-glucosidase inhibitors and alternative agent for control of type 1 diabetes.
Effects of prolonged (6 months) alpha-glucosidase inhibition on blood glucose control and insulin requirements in patients with insulin-dependent diabetes mellitus.
Effects of prolonged administration of two new alpha-glucosidase inhibitors on blood glucose control, insulin requirements and breath hydrogen excretion in patients with insulin-dependent diabetes mellitus.
Effects of two new alpha-glucosidase inhibitors on glycemic control in patients with insulin-dependent diabetes mellitus.
Nocturnal hypoglycemia in type 1 diabetes: an assessment of preventive bedtime treatments.
Oral hypoglycemic agents: insulin secretagogues, alpha-glucosidase inhibitors and insulin sensitizers.
[Valibose, an alpha-glucosidase inhibitor, ameliorates the metabolic disorder of glucose and lipids and the nephropathy in streptozotocin-induced diabetic rats].
Diabetes Mellitus, Type 2
A cardiologic approach to non-insulin antidiabetic pharmacotherapy in patients with heart disease.
A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44)
A randomized, double-blind, placebo-controlled trial to assess safety and tolerability during treatment of type 2 diabetes with usual diabetes therapy and either Cycloset or placebo.
A TLC bioautographic method for the detection of alpha- and beta-glucosidase inhibitors in plant extracts.
Acarbose attenuates experimental non-alcoholic steatohepatitis.
Acarbose for the treatment of type II diabetes: the results of a Canadian multi-centre trial.
Acarbose improves glycemic control and reduces body weight: Subanalysis data of South Asia region.
Acarbose in the treatment of elderly patients with type 2 diabetes.
Acarbose is a promising therapeutic strategy for the treatment of patients with nonalcoholic steatohepatitis (NASH).
Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance.
Acarbose treatment of non-insulin-dependent diabetes mellitus.
Advantages of alpha-glucosidase inhibition as monotherapy in elderly type 2 diabetic patients.
Alpha glucosidase inhibition in the treatment of non-insulin-dependent diabetes mellitus.
alpha-Glucosidase inhibition by miglitol in NIDDM patients.
alpha-Glucosidase inhibitor reduces the progression of carotid intima-media thickness.
Alpha-glucosidase inhibitor use is associated with decreased colorectal neoplasia risk in patients with type 2 diabetes mellitus receiving colonoscopy: a retrospective study.
Alpha-glucosidase inhibitor, acarbose, improves glycamic control and reduces body weight in type 2 diabetes: Findings on indian patients from the pooled data analysis.
Alpha-glucosidase inhibitors and hepatotoxicity in type 2 diabetes: a systematic review and meta-analysis.
Alpha-glucosidase inhibitors for patients with type 2 diabetes: response to van de Laar et al.
Alpha-glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis.
Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose.
Alpha-glucosidase inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type 2 diabetes mellitus.
Alpha-glucosidase inhibitors for type 2 diabetes mellitus.
alpha-Glucosidase inhibitors in diabetes: efficacy in NIDDM subjects.
alpha-Glucosidase inhibitors in diabetes: lessons from animal studies.
Alpha-glucosidase inhibitors in the early treatment of type 2 diabetes.
Alpha-glucosidase inhibitors may reduce the risk of type 2 diabetes.
An ?-glucosidase inhibitor could reduce T-wave alternans in type 2 diabetes patients.
An alpha-glucosidase inhibitor, acarbose treatment decreases serum levels of glyceraldehyde-derived advanced glycation end products (AGEs) in patients with type 2 diabetes.
An importance of carbohydrate ingestion for the expression of the effect of alpha-glucosidase inhibitor in NIDDM.
Association between ?-glucosidase inhibitor use and psoriatic disease risk in patients with type 2 diabetes mellitus: A population-based cohort study.
Beneficial effect of long-term combined treatment with voglibose and pioglitazone on pancreatic islet function of genetically diabetic GK rats.
Beneficial effects of vildagliptin combined with miglitol on glucose tolerance and islet morphology in diet-controlled db/db mice.
Blood glucose-lowering activity of colestimide in patients with type 2 diabetes and hypercholesterolemia: a case-control study comparing colestimide with acarbose.
Can alpha-glucosidase inhibitors reduce the dosage of sulphonylurea compounds needed by patients with non-insulin-dependent diabetes mellitus?
Can alpha-glucosidase inhibitors reduce the insulin dosage administered to patients with non-insulin-dependent diabetes mellitus?
Changes in alpha-glucosidase activities along the jejunal-ileal axis of normal rats by the alpha-glucosidase inhibitor miglitol.
Characteristics of Food Protein-Derived Antidiabetic Bioactive Peptides: A Literature Update.
Chronic treatment of African-American type 2 diabetic patients with alpha-glucosidase inhibition.
Clinical effect of combination therapy of pioglitazone and an alpha-glucosidase inhibitor.
Clinical evaluation of pioglitazone in patients with type 2 diabetes using alpha-glucosidase inhibitor and examination of its efficacy profile.
Combination of oral antidiabetic drugs and insulin in the treatment of non-insulin-dependent diabetes.
Combination therapy of alpha-glucosidase inhibitor and a sulfonylurea compound prolongs the duration of good glycemic control.
Comparative safety of newer oral antidiabetic drugs.
Comparison of effects of sitagliptin and voglibose on left ventricular diastolic dysfunction in patients with type 2 diabetes: results of the 3D trial.
Comparison of Lipid-Lowering Effects of Anagliptin and Miglitol in Patients With Type 2 Diabetes: A Randomized Trial.
Comparison of the effect of glucose-lowering agents on the risk of atrial fibrillation: A network meta-analysis.
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2016 EXECUTIVE SUMMARY.
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2017 EXECUTIVE SUMMARY.
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2018 EXECUTIVE SUMMARY.
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2019 EXECUTIVE SUMMARY.
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2020 EXECUTIVE SUMMARY.
Considerations when using alpha-glucosidase inhibitors in the treatment of type 2 diabetes.
Correlations of fasting and postprandial blood glucose increments to the overall diurnal hyperglycemic status in type 2 diabetic patients: variations with levels of HbA1c.
Dose-dependent efficacy of miglitol, an alpha-glucosidase inhibitor, in type 2 diabetic patients on diet alone: results of a 24-week double-blind placebo-controlled study.
Dose-response profile of acarbose in older subjects with type 2 diabetes.
DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE study.
Effect of acarbose (alpha-glucosidase inhibitor) on disaccharase activity in small intestine in KK-Ay and ddY mice.
Effect of acarbose (BAY-g-5421) on expression of noninsulin-dependent diabetes mellitus in sucrose-fed SHR/N-corpulent rats.
Effect of acarbose on glucose intolerance in patients with non-insulin-dependent diabetes mellitus.
Effect of acarbose on insulin sensitivity in elderly patients with diabetes.
Effect of acarbose on postprandial lipid metabolism in type 2 diabetes mellitus.
Effect of acarbose, an alpha-glucosidase inhibitor, on serum lipoprotein lipase mass levels and common carotid artery intima-media thickness in type 2 diabetes mellitus treated by sulfonylurea.
Effect of alpha-glucosidase inhibitor in combination with sulphonylurea compounds on lipid profile in patients with non-insulin-dependent diabetes mellitus.
Effect of an alpha-glucosidase inhibitor (voglibose), in combination with sulphonylureas, on glycaemic control in type 2 diabetes patients.
Effect of an alpha-glucosidase inhibitor combined with sulphonylurea treatment on glucose metabolism in patients with non-insulin-dependent diabetes mellitus.
Effect of an alpha-glucosidase inhibitor on intestinal fermentation and faecal lipids in diabetic patients.
Effect of Ca(2+) on the activity and structure of ?-glucosidase: Inhibition kinetics and molecular dynamics simulations.
Effect of pioglitazone on muscle sympathetic nerve activity in type 2 diabetes mellitus with alpha-glucosidase inhibitor.
Effect of race on the glycaemic response to sitagliptin: Insights from the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).
Effects of alpha-glucosidase inhibitor (acarbose) combined with sulfonylurea or sulfonylurea and metformin in treatment of non-insulin-dependent diabetes mellitus.
Effects of BAYm 1099, new alpha-glucosidase inhibitor, on acute metabolic responses and metabolic control in NIDDM over 1 mo.
Effects of beano on the tolerability and pharmacodynamics of acarbose.
Effects of changeover from voglibose to acarbose on postprandial triglycerides in type 2 diabetes mellitus patients.
Effects of current therapeutic interventions on insulin resistance.
Effects of L-malic Acid on alpha-glucosidase: inhibition kinetics and computational molecular dynamics simulations.
Effects of long-term treatment with alpha-glucosidase inhibitor on the peripheral nerve function and structure in Goto-Kakizaki rats: a genetic model for type 2 diabetes.
Effects of voglibose on glycemic excursions, insulin secretion, and insulin sensitivity in non-insulin-treated NIDDM patients.
Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind trial.
Efficacy of 24-week monotherapy with acarbose, glibenclamide, or placebo in NIDDM patients. The Essen Study.
Efficacy of alpha-glucosidase inhibitors on lipids in NIDDM subjects with moderate hyperlipidaemia.
Efficacy of combined use of miglitol in Type 2 diabetes patients receiving insulin therapy-placebo-controlled double-blind comparative study.
Emerging strategies for the activity assay and inhibitor screening of alpha-glucosidase.
Evaluation of antihyperglycemia and antihypertension potential of native Peruvian fruits using in vitro models.
Evaluation of indigenous grains from the Peruvian Andean region for antidiabetes and antihypertension potential using in vitro methods.
Glitazones and alpha-glucosidase inhibitors as the second-line oral anti-diabetic agents added to metformin reduce cardiovascular risk in Type 2 diabetes patients: a nationwide cohort observational study.
Improving management of type 2 diabetes mellitus: 1. alpha-Glucosidase inhibitors.
In vitro alpha-glucosidase and alpha-amylase enzyme inhibitory effects of Andrographis paniculata extract and andrographolide.
In vitro potential of Ascophyllum nodosum phenolic antioxidant-mediated alpha-glucosidase and alpha-amylase inhibition.
Incretin-based therapies in the management of type 2 diabetes: rationale and reality in a managed care setting.
Inhibition of alpha-glucosidase by aqueous extracts of some potent antidiabetic medicinal herbs.
Inhibition of postprandial hyperglycemia by acarbose is a promising therapeutic strategy for the treatment of patients with the metabolic syndrome.
Inhibitory effect of koji Aspergillus terreus on alpha-glucosidase activity and postprandial hyperglycemia.
Inhibitory effect of phloroglucinol on ?-glucosidase: Kinetics and molecular dynamics simulation integration study.
Insulin secretion levels necessary for efficacy of an alpha-glucosidase inhibitor on glucose metabolism in patients with non-insulin-dependent diabetes mellitus.
Is there a role for alpha-glucosidase inhibitors in the prevention of type 2 diabetes mellitus?
Long-term effect of alpha-glucosidase inhibitor on late dumping syndrome.
Long-term effectiveness of a new alpha-glucosidase inhibitor (BAY m1099-miglitol) in insulin-treated type 2 diabetes mellitus.
Long-term outcomes of adding alpha-glucosidase inhibitors in insulin-treated patients with type 2 diabetes.
Long-term titrated-dose alpha-glucosidase inhibition in non-insulin-requiring Hispanic NIDDM patients.
Low-dose acarbose improves glycemic control in NIDDM patients without changes in insulin sensitivity.
Management of non-insulin-dependent diabetes mellitus.
Meta-analysis and critical review on the efficacy and safety of alpha-glucosidase inhibitors in Asian and non-Asian populations.
Meta-analysis of the impact of alpha-glucosidase inhibitors on incident diabetes and cardiovascular outcomes.
Mitiglinide: KAD 1229, S 21403.
New glucosidase inhibitors from an ayurvedic herbal treatment for type 2 diabetes: structures and inhibition of human intestinal maltase-glucoamylase with compounds from Salacia reticulata.
No effect of an alpha-glucosidase inhibitor on glucose metabolism in patients with non-insulin-dependent diabetes mellitus and low function of pancreatic beta cells.
Oral antidiabetic agents. The emergence of alpha-glucosidase inhibitors.
Oral hypoglycemic agents: insulin secretagogues, alpha-glucosidase inhibitors and insulin sensitizers.
Pharmacokinetics of oral antihyperglycaemic agents in patients with renal insufficiency.
Pharmacologic management of the older patient with type 2 diabetes mellitus.
Phenolic-linked variation in strawberry cultivars for potential dietary management of hyperglycemia and related complications of hypertension.
Pioglitazone produces rapid and persistent reduction of vascular inflammation in patients with hypertension and type 2 diabetes mellitus who are receiving angiotensin II receptor blockers.
Pioglitazone: a review of Japanese clinical studies.
Pneumatosis cystoides intestinalis of the ascending colon related to acarbose treatment: a case report.
Potential antiradical and alpha-glucosidase inhibitors from Ecklonia maxima (Osbeck) Papenfuss.
Pu-erh tea polysaccharides decrease blood sugar by inhibition of ?-glucosidase activity in vitro and in mice.
Punica granatum flower extract, a potent alpha-glucosidase inhibitor, improves postprandial hyperglycemia in Zucker diabetic fatty rats.
Reappraisal of the pharmacologic approach to treatment of type 2 diabetes mellitus.
Relationship between gastric emptying and an alpha-glucosidase inhibitor effect on postprandial hyperglycemia in NIDDM patients.
Review: alpha-glucosidase inhibitors improve glycemic control but have uncertain effects on patient-important outcomes in type 2 diabetes.
Safety, tolerability and efficacy of lixisenatide in combination with oral antidiabetic treatment in Japanese patients with type 2 diabetes: An open-label, multicenter study.
Sex-dependent Differences in Liver and Gut Metabolomic Profiles with Acarbose and Calorie Restriction in C57BL/6 Mice.
Starch digestion, large-bowel fermentation and intestinal mucosal cell proliferation in rats treated with the alpha-glucosidase inhibitor acarbose.
Study of the inhibition of two human maltase-glucoamylases catalytic domains by different ?-glucosidase inhibitors.
Synergisms in Alpha-glucosidase Inhibition and Antioxidant Activity of Camellia sinensis L. Kuntze and Eugenia uniflora L. Ethanolic Extracts.
Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus.
The alpha-glucosidase inhibitor acarbose prevents obesity and simple steatosis in sequestosome 1/A170/p62 deficient mice.
The alpha-glucosidase inhibitor acarbose reduces the net electronegative charge of low-density lipoprotein in patients with newly diagnosed type 2 diabetes.
The alpha-glucosidase inhibitor miglitol decreases glucose fluctuations and inflammatory cytokine gene expression in peripheral leukocytes of Japanese patients with type 2 diabetes mellitus.
The clinical efficacy of a second-generation alpha-glucosidase inhibitor in non-insulin-dependent diabetic patients.
The effect of a very low dose of tolbutamide combined with an alpha-glucosidase inhibitor in non-insulin-dependent diabetes mellitus.
The effect of an alpha-glucosidase inhibitor and insulin on glucose metabolism and lipid profiles in non-insulin-dependent diabetes mellitus.
The efficacy and safety of miglitol therapy compared with glibenclamide in patients with NIDDM inadequately controlled by diet alone.
The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial.
The hypoglycemic activity of Euclea undulata Thunb. var. myrtina (Ebenaceae) root bark evaluated in a streptozotocin–nicotinamide induced type 2 diabetes rat model
The STOP-NIDDM Trial: an international study on the efficacy of an alpha-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data. Study to Prevent Non-Insulin-Dependent Diabetes Mellitus.
The synthesis and biological evaluation of 1-C-alkyl-L-arabinoiminofuranoses, a novel class of ?-glucosidase inhibitors.
The use of insulin secretagogues in the treatment of type 2 diabetes.
Treatment of type 2 diabetes mellitus in children and adolescents.
Type 2 diabetes mellitus: what is the optimal treatment regimen?
Use of an alpha-glucosidase inhibitor to synchronize sugar absorption with delayed insulin secretion in a patient with non-insulin-dependent diabetes mellitus.
Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance.
[Acarbose (glucobai) effects on lipid metabolism in patients with non-insulin dependent diabetes mellitus]
[Alpha-glucosidase inhibitor and insulin sensitizer combination therapy in NIDDM]
[Alpha-glucosidase inhibitor for the prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese subjects with impaired glucose tolerance]
[Clinical trials to evaluate interventions aimed to prevent or delay the development of diabetes in high risk IGT]
[Current status of the treatment of type 2 diabetes mellitus. Alpha-glucosidase inhibitors]
[Efficacy of combination therapy of alpha-glucosidase inhibitor and insulin sensitizer in patients with type 2 diabetes]
[Hypoglycemia in the diabetes treatment - risk minimization with dipeptidyl peptidase-4 inhibitors].
[Info-Meeting. Pharmacologic prevention of the progression from impaired glucose tolerance to type 2 diabetes: favorable effects of metformin and acarbose]
[Molecular targets for new drug discovery to treat type 2 diabetes and obesity]
[Non-insulin-dependent diabetes mellitus associated with nonalcoholic liver cirrhosis: an evaluation of treatment with the intestinal alpha-glucosidase inhibitor acarbose]
[Occurrence of ileus after voglibose treatment in an elderly diabetic patient with gait disturbance caused by cerebral hemorrhage]
[Pitfalls in treatment with oral antidiabetic agents]
[Synthetic medicinal chemistry of the biomolecular components mimics].
[The alpha-glucosidase inhibitor miglitol for the treatment of type 2 diabetes mellitus in the doctor's office]
[Treatment of type 2 diabetes mellitus with the alpha-glucosidase inhibitor Miglitol in the doctor's office]
[Use of oral hypoglycemic agents in patients with chronic kidney failure.]
Diabetic Ketoacidosis
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2016 EXECUTIVE SUMMARY.
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2019 EXECUTIVE SUMMARY.
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2020 EXECUTIVE SUMMARY.
Diabetic Neuropathies
Pneumatosis cystoides intestinalis of the ascending colon related to acarbose treatment: a case report.
Diabetic Retinopathy
Macrophage foam cell formation is augmented in serum from patients with diabetic angiopathy.
Diphtheria
STUDIES ON BACTERIAL ENZYMES : VI. THE MALTASE OF THE DIPHTHERIA BACILLUS.
Disorders of Excessive Somnolence
Sleep-related obstructive and nonobstructive apneas and neurologic disorders.
Diverticulum
alpha-Glucosidase of oyster (Crassostrea gigas) digestive diverticula.
Dumping Syndrome
Acute and long-term effect of alpha-glucosidase inhibitor on dumping syndrome in a patient after a vagotomy and pyloric surgery.
Concurrent Therapy with a Low-carbohydrate Diet and Miglitol Remarkably Improved the Postprandial Blood Glucose and Insulin Levels in a Patient with Reactive Hypoglycemia due to Late Dumping Syndrome.
Effect of acarbose on the 24-hour blood glucose profile and pattern of carbohydrate absorption.
Long-term effect of alpha-glucosidase inhibitor on late dumping syndrome.
[The effect of alpha-glucosidase inhibitor on burning epigastralgia in dumping syndrome: a case report]
Duodenal Ulcer
Study of enzyme activities in the descending part of the duodenum in patients of duodenal ulcer.
Duodenitis
Low activities of disaccharidases associated with inflamed duodenal bulb mucosa.
Dyslipidemias
Improvement of insulin sensitivity and dyslipidemia with a new alpha-glucosidase inhibitor, voglibose, in nondiabetic hyperinsulinemic subjects.
In vitro inhibitory effects of Limonium contortirameum and L. virgatum extracts from sardinia on alpha-amylase, alpha-glucosidase and pancreatic lipase.
Dyspnea
Optoelectronic plethysmography as an alternative method for the diagnosis of unilateral diaphragmatic weakness.
Encephalomyelitis, Autoimmune, Experimental
Inhibition of experimental allergic encephalomyelitis by the alpha-glucosidase inhibitor castanospermine.
Enteritis
[Maltase activity in the small intestine during chronic enteritis]
[Maltase activity of the small intestine in chronic enteritis]
Epididymitis
The influence of inflammation of the human male genital tract on secretion of the seminal markers alpha-glucosidase, glycerophosphocholine, carnitine, fructose and citric acid.
Epstein-Barr Virus Infections
A rare presentation of childhood pompe disease: cardiac involvement provoked by Epstein-Barr virus infection.
Exocrine Pancreatic Insufficiency
Influence of exocrine and endocrine pancreatic function on intestinal brush border enaymatic activities.
Fabry Disease
Biological properties of D- and L-1-deoxyazasugars.
Biotherapeutic target or sink: analysis of the macrophage mannose receptor tissue distribution in murine models of lysosomal storage diseases.
Lysosomal storage diseases.
Uptake of lysosomal enzymes by human fibroblasts: lack of uptake of fungal or plant glycosidases in comparison with a mammalian enzyme.
Fatty Liver
alpha-Glucosidase inhibitor acarbose and sequestome 1/A170/p62 deficient mice: A promising therapy and unique model for non-alcoholic fatty liver disease.
Inhibitory effect of a new alpha-glucosidase inhibitor on fatty liver in Zucker fatty rats.
[The effect of an alpha-glucosidase inhibitor on fatty liver in obesity]
Fetal Growth Retardation
Effect of intrauterine growth retardation on the activities of fetal intestinal enzymes in rats.
Fructose Intolerance
Fructose-free diet effects on intestinal alpha-glucosidase activities in hereditary fructose intolerance.
Gastroenteritis
The role of probiotic cultures in the control of gastrointestinal health.
Gastroesophageal Reflux
Brush border enzyme activities in relation to histological lesion in pediatric celiac disease.
Gastrointestinal Diseases
The Role of Disaccharidase Deficiencies in Functional Abdominal Pain Disorders-A Narrative Review.
The role of probiotic cultures in the control of gastrointestinal health.
Gaucher Disease
Lysosomal storage diseases.
Genetic Diseases, Inborn
Infantile-onset Pompe disease: Diagnosis and management.
Giardiasis
Disaccharidase deficiencies in Mongolian gerbils (Meriones unguiculatus) protected against Giardia lamblia.
[Enzymes and histology of the intestinal mucosa of breast-fed African infants]
Glioblastoma
Activity of glycogen depolymerizing enzymes in extracts from brain tumor tissue (anaplastic astrocytoma and glioblastoma multiforme).
Glomerulonephritis, Membranous
Microdomains of distinctive glycoprotein composition in the kidney proximal tubule brush border.
glucan 1,4-alpha-glucosidase deficiency
A cross-sectional single-centre study on Pompe disease in 42 German patients: Molecular analysis of the GAA gene, manifestation and genotype-phenotype correlations.
alpha-Glucosidase isoenzymes in normal and acid maltase-deficient human skeletal muscles.
Genotype-phenotype correlation in adult-onset acid maltase deficiency.
Immunocytochemical analysis of normal and acid maltase-deficient muscle cultures.
Infantile-onset Pompe disease: Diagnosis and management.
Late-onset acid maltase deficiency. Biochemical studies of leukocytes.
Multiple neutral maltase activities in normal and acid maltase-deficient human muscle.
New kind of cytoplasmic inclusions of plasma cells in acid maltase deficiency.
Patients with functional bowel disorder have disaccharidase deficiency: A single-center study from Russia.
Reappearance of embryonic neutral alpha-glucosidase isoenzyme in acid maltase-deficient muscle of Japanese quail.
Selective vacuolar myopathy with atrophy of type II fibers. Occurrence in a childhood case of acid maltase deficiency.
Small intestinal glucoamylase deficiency and starch malabsorption: a newly recognized alpha-glucosidase deficiency in children.
Treatment of acid maltase deficiency with a diet high in branched-chain amino acids.
Tris discriminates between the different alpha-glucosidase activities from extracts of human neutrophils.
[Disaccharidase deficiency and functional bowel diseases].
Glucose Intolerance
Acarbose is a promising therapeutic strategy for the treatment of patients with nonalcoholic steatohepatitis (NASH).
Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial.
Acarbose, an alpha-glucosidase inhibitor, decreases aortic gene expression and serum levels of monocyte chemoattractant protein-1 in fructose-fed rats.
Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose.
Alpha-glucosidase inhibitors in the early treatment of type 2 diabetes.
Comparative safety of newer oral antidiabetic drugs.
Does Treatment of Impaired Glucose Tolerance Improve Cardiovascular Outcomes in Patients with Previous Myocardial Infarction?
Effect of acarbose on glucose intolerance in patients with non-insulin-dependent diabetes mellitus.
Effect of inhibition of alpha-glucosidase on age-related glucose intolerance and pancreatic atrophy in rats.
Effects of a late evening snack combined with alpha-glucosidase inhibitor on liver cirrhosis.
Effects of acarbose on proinsulin and insulin secretion and their potential significance for the intermediary metabolism and cardiovascular system.
Impaired glucose homeostasis in young adult thalassemic patients: a pilot study with acarbose.
Inhibition of postprandial hyperglycemia by acarbose is a promising therapeutic strategy for the treatment of patients with the metabolic syndrome.
Plasma BNP Levels and Diuretics Use as Predictors of Cardiovascular Events in Patients with Myocardial Infarction and Impaired Glucose Tolerance.
Potential of alpha-glucosidase inhibitors in elderly patients with diabetes mellitus and impaired glucose tolerance.
The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance.
The STOP-NIDDM Trial: an international study on the efficacy of an alpha-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data. Study to Prevent Non-Insulin-Dependent Diabetes Mellitus.
Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance.
[Alpha-glucosidase inhibitor for the prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese subjects with impaired glucose tolerance]
[Cardiovascular effects of oral hypoglycemie drugs]
[Effects of acarbose, alpha-glucosidase inhibitor in treatment of impaired glucose tolerance]
[Effects of voglibose, alpha-glucosidase inhibitor in treatment of impaired glucose tolerance]
[Info-Meeting. Pharmacologic prevention of the progression from impaired glucose tolerance to type 2 diabetes: favorable effects of metformin and acarbose]
[Prevention of the manifestation of diabetes in the elderly in the presymptomatic stage]
Glycogen Storage Disease
A micro-radiochemical assay for alpha-1,4-glucosidase and its use in the assessment of type II glycogenosis (Pompe's disease).
A microfluorometric assay of leukocyte alpha-1,4-glucosidase.
A sensitive semi-automated kinetic assay of alpha-D-glucosidase for the prenatal diagnosis of type 2 glycogenosis (Pompe's disease).
Acid alpha-glucosidase deficiency (glycogenosis type II, Pompe disease).
Adeno-associated virus-mediated transfer of human acid maltase gene results in a transient reduction of glycogen accumulation in muscle of Japanese quail with acid maltase deficiency.
Adult forms of glycogenosis type II. A defect in an early stage of acid alpha-glucosidase realization.
Age-related decline in muscle strength and power output in acid 1-4 alpha-glucosidase knockout mice.
Alglucosidase alfa enzyme replacement therapy as a therapeutic approach for glycogen storage disease type III.
Alglucosidase alfa treatment alleviates liver disease in a mouse model of glycogen storage disease type IV.
Alpha-glucosidase administration: experiences in two patients with glycogen storage disease compared with animal experiments.
alpha1,4-Glucosidase-albumin polymers: in vitro properties and advantages for enzyme replacement therapy.
Angiocardiographic and enzyme studies in a patient with type II glycogenosis (Pompe's disease). A case report.
Biochemical genetics of the Lapland dog model of glycogen storage disease type II (acid alpha-glucosidase deficiency).
Bovine generalised glycogenosis type II. Uptake of lysosomal alpha-glucosidase by cultured skeletal muscle and reversal of glycogen accumulation.
Broad spectrum of Pompe disease in patients with the same c.-32-13T->G haplotype.
Canine glycogen storage disease type II. A biochemical study of an acid alpha-glucosidase-deficient Lapland dog.
Cell-free translation of human lysosomal alpha-glucosidase: evidence for reduced precursor synthesis in an adult patient with glycogenosis type II.
Clinical diversity in glycogenosis type II. Biosynthesis and in situ localization of acid alpha-glucosidase in mutant fibroblasts.
Clinical manifestation and natural course of late-onset Pompe's disease in 54 Dutch patients.
Common antigenicity for two glycosidases.
Comparative pathology of the canine model of glycogen storage disease type II (Pompe's disease).
Correction of multiple striated muscles in murine Pompe disease through adeno-associated virus-mediated gene therapy.
Decreased activity of acid alpha-glucosidase in a patient with persistent periocular swelling after infusions of hydroxyethyl starch.
Diagnosis of Pompe disease: muscle biopsy vs blood-based assays.
Differential muscular glycogen clearance after enzyme replacement therapy in a mouse model of Pompe disease.
Dominantly inherited cardioskeletal myopathy with lysosomal glycogen storage and normal acid maltase levels.
Enzyme replacement therapy for infantile Pompe disease during the critical period and identification of a novel mutation.
Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial.
Evidence of molecular heterogeneity for generalised glycogenosis between and within breeds of cattle.
Extended phenotype description and new molecular findings in late onset glycogen storage disease type II: a northern Italy population study and review of the literature.
First trimester diagnosis of Pompe's disease (glycogenosis type II) with normal outcome: assay of acid alpha-glucosidase in chorionic villous biopsy using antibodies.
Frequent mutation in Chinese patients with infantile type of GSD II in Taiwan: evidence for a founder effect.
Genetic defects in patients with glycogenosis type II (acid maltase deficiency).
Genotyping Brahman cattle for generalised glycogenosis.
Genotyping shorthorn cattle for generalised glycogenosis.
Glycogen storage disease type I. Results of treatment with frequent daytime feeding, combined with nocturnal intragastric feeding and with administration of an alpha-glucosidase inhibitor.
Glycogenosis type II (acid maltase deficiency).
Heterozygote detection in a family of Lapland dogs with a recessively inherited metabolic disease: canine glycogen storage disease type II.
Hydrostatic isolated limb perfusion with adeno-associated virus vectors enhances correction of skeletal muscle in Pompe disease.
Identification of a de novo point mutation resulting in infantile form of Pompe's disease.
Identification of a small deletion in one allele of patients with infantile form of glycogen storage disease type II.
Immunochemical studies of human acid alpha-1,4-glucosidase in type II glycogenosis.
Infantile-onset Pompe disease: Diagnosis and management.
Inhibition of bovine alpha-glucosidase by Castanospermum australe and its effect on the biochemical identification of heterozygotes for generalised glycogenosis type II (Pompe's disease) in cattle.
Late-Onset Glycogen Storage Disease Type II (Pompe's Disease) with a Novel Mutation: A Malaysian Experience.
Leucocyte alpha-1,4- and alpha-1,6-glucosidase activities towards oligosaccharides in late onset glycogenosis type II.
Lymphocyte alpha-glucosidase in late-onset glycogenosis type II.
Lysosomal glycogen storage mimicking the cytological picture of Pompe's disease as induced in rats by injection of an alpha-glucosidase inhibitor. I. Alterations in liver.
Molecular diagnosis of German patients with late-onset glycogen storage disease type II.
New insights into therapeutic options for Pompe disease.
Nosology of lysosomal glycogen storage diseases without in vitro acid maltase deficiency. Delineation of a neonatal form.
Partial characterization of leucocyte alpha-glucosidase in late onset glycogenosis type II.
Pompe disease: a review of the current diagnosis and treatment recommendations in the era of enzyme replacement therapy.
Preparation of monoclonal antibodies against acid alpha-D-glucosidase for study of Chinese glycogenosis type II patients.
Progress in Enzyme Replacement Therapy in Glycogen Storage Disease Type II.
Properties of the alpha-glucosidase from various human tissues in relation to glycogenosis type II (Pompe's disease).
Screening for Pompe disease using a rapid dried blood spot method: experience of a clinical diagnostic laboratory.
Simultaneous absence of alpha-1,4-glucosidase and alpha-1,6-glucosidase activities (pH 4) in tissues of children with type II glycogen storage disease.
The electrophoretic pattern and activities of acid and neutral maltase of cultivated fibroblasts and amniotic fluid cells from controls and patients with the variant of glycogen storage disease type II (Pompe's disease).
Therapeutic approaches in glycogen storage disease type II/Pompe Disease.
Tris discriminates between the different alpha-glucosidase activities from extracts of human neutrophils.
Two extremes of the clinical spectrum of glycogen storage disease type II in one family: a matter of genotype.
Ultrastructure of the eye in fetal type II glycogenosis (Pompe's disease).
Using human Pompe disease-induced pluripotent stem cell-derived neural cells to identify compounds with therapeutic potential.
Zonal differences of alpha-glucosidases in human kidney: studies in controls and in patients with glycogenosis type II.
[Biochemical diagnosis of glycogenosis type II (acid maltase deficiency) (author's transl)]
[Cardiomuscular lysosomal glycogenosis in adults without known enzyme deficiency. A cause of familial myocardiopathy and lysosomal glycogen overload with normal acid maltase]
[Characterization of alpha-glucosidase in skin fibroblasts in the diagnosis of glycogenosis type 2 (Pompe disease)]
[Heterogeneity of glycogenosis with alpha-1,4-glucosidase deficiency: enzymatic studies in three families (author's transl)]
[Immunochemical study of acid alpha-1,4-glucosidase in 7 patients with type II glycogenosis]
[Muscular glycogenosis caused by alpha-1,4-glucosidase deficiency simulating progressive muscular dystrophy. (Clinical and enzyme study. Optic and electron microscopy)]
[ON A SPECIAL FORM OF GIERKE'S GLYCOGENOSIS WITH INCREASED ALPHA-GLUCOSIDASE ACTIVITY IN THE LIVER AND COMPLETE LACK OF GLUCOSE-6-PHOSPHATASE.]
[Pompe and his disease].
[Pseudodystrophic muscle glycogenosis in adults. (Acid maltase deficiency syndrome) (author's transl)]
[Tests for the detection of inborn errors of metabolism--urinary alpha-glucosidase analysis for the detection of glycogen storage disease type II (author's transl)]
Glycogen Storage Disease Type I
Glycogen storage disease type I. Results of treatment with frequent daytime feeding, combined with nocturnal intragastric feeding and with administration of an alpha-glucosidase inhibitor.
Glycogen Storage Disease Type II
36 months observational clinical study of 38 adult Pompe disease patients under alglucosidase alfa enzyme replacement therapy.
A 4-Year Observational Clinical Study of 24 Adult Pompe Disease Patients under Alglucosidase Alfa Enzyme Replacement Therapy.
A case of adult Pompe disease presenting with severe fatigue and selective involvement of type 1 muscle fibers.
A cross-sectional single-centre study on Pompe disease in 42 German patients: Molecular analysis of the GAA gene, manifestation and genotype-phenotype correlations.
A fluorometric assay of alpha-glucosidase and its application in the study of Pompe's disease.
A micro-radiochemical assay for alpha-1,4-glucosidase and its use in the assessment of type II glycogenosis (Pompe's disease).
A microfluorometric assay of leukocyte alpha-1,4-glucosidase.
A molecular analysis of the GAA gene and clinical spectrum in 38 patients with Pompe disease in Japan.
A new assay for fast, reliable CRIM status determination in infantile-onset Pompe disease.
A new resorufin-based alpha-glucosidase assay for high-throughput screening.
A Phase 4 Prospective Study in Patients with Adult Pompe Disease Treated with Alglucosidase Alfa.
A randomized study of alglucosidase alfa in late-onset Pompe's disease.
A rare presentation of childhood pompe disease: cardiac involvement provoked by Epstein-Barr virus infection.
A review of treatment of Pompe disease in infants.
Abnormal mannose-6-phosphate receptor trafficking impairs recombinant alpha-glucosidase uptake in Pompe disease fibroblasts.
Abnormal trafficking of sarcolemmal proteins in alpha-glucosidase deficiency.
Acid alpha-glucosidase deficiency (glycogenosis type II, Pompe disease).
Acid maltase deficiency and related myopathies.
Adeno-associated virus-mediated transfer of human acid maltase gene results in a transient reduction of glycogen accumulation in muscle of Japanese quail with acid maltase deficiency.
Adult forms of glycogenosis type II. A defect in an early stage of acid alpha-glucosidase realization.
Adult Pompe disease: Clinical manifestations and outcome of the first Greek patients receiving enzyme replacement therapy.
Adult-onset acid maltase deficiency. Case report of an adult with severe respiratory difficulty.
Age-related decline in muscle strength and power output in acid 1-4 alpha-glucosidase knockout mice.
Alglucosidase alfa and Pompe disease: still going strong?
Alglucosidase alfa therapy for Pompe disease in pregnancy - Case report.
Alglucosidase alfa: Long term use in the treatment of patients with Pompe disease.
Alglucosidase alfa: new drug. Pompe disease: a short-term benefit.
alpha-glucosidase (CHO) (Genzyme).
alpha-glucosidase activity in human leucocytes: choice of lymphocytes for the diagnosis of Pompe's disease and the carrier state.
alpha-Glucosidase deficiency (Pompe's disease).
Alpha-glucosidase deficiency and basilar artery aneurysm: report of a sibship.
Alpha-glucosidase deficiency in a child.
alpha-Glucosidase deficiency in generalized glycogenstorage disease (Pompe's disease).
alpha-Glucosidase in Pompe's disease.
alpha-Glucosidase isoenzymes in normal and acid maltase-deficient human skeletal muscles.
Amniotic cell 4-methylumbelliferyl-alpha-glucosidase activity for prenatal diagnosis of Pompe's disease.
An individually, modified approach to desensitize infants and young children with Pompe disease, and significant reactions to alglucosidase alfa infusions.
Antisense Oligonucleotide-mediated Suppression of Muscle Glycogen Synthase 1 Synthesis as an Approach for Substrate Reduction Therapy of Pompe Disease.
Assessing metabolic profiles in human myoblasts from patients with late-onset Pompe disease.
At-Risk Testing for Pompe Disease Using Dried Blood Spots: Lessons Learned for Newborn Screening.
Attitudes and expectations of patients with neuromuscular diseases about their participation in a clinical trial.
Atypical immunologic response in a patient with CRIM-negative Pompe disease.
Biochemical and pharmacological characterization of different recombinant acid alpha-glucosidase preparations evaluated for the treatment of Pompe disease.
Biochemical genetics of the Lapland dog model of glycogen storage disease type II (acid alpha-glucosidase deficiency).
Biopsy-proven alpha-glucosidase deficiency with normal lymphocyte enzyme activity.
Biosynthesis of acid alpha-glucosidase in late-onset forms of glycogenosis type II (Pompe's disease).
Biotherapeutic target or sink: analysis of the macrophage mannose receptor tissue distribution in murine models of lysosomal storage diseases.
Bortezomib in the rapid reduction of high sustained antibody titers in disorders treated with therapeutic protein: lessons learned from Pompe disease.
Bovine generalised glycogenosis type II. Uptake of lysosomal alpha-glucosidase by cultured skeletal muscle and reversal of glycogen accumulation.
Broad spectrum of Pompe disease in patients with the same c.-32-13T->G haplotype.
Canine glycogen storage disease type II. A biochemical study of an acid alpha-glucosidase-deficient Lapland dog.
Cardiac remodeling after enzyme replacement therapy with acid alpha-glucosidase for infants with Pompe disease.
Cardiac responses in paediatric Pompe disease in the ADVANCE patient cohort.
Cardiopulmonary exercise test to quantify enzyme replacement response in pediatric Pompe disease.
Cell-free translation of human lysosomal alpha-glucosidase: evidence for reduced precursor synthesis in an adult patient with glycogenosis type II.
Cessation and resuming of alglucosidase alfa in Pompe disease: a retrospective analysis.
Challenges in treating Pompe disease: an industry perspective.
Characterization of the molecular defect in infantile and adult acid alpha-glucosidase deficiency fibroblasts.
Clinical and metabolic correction of pompe disease by enzyme therapy in acid maltase-deficient quail.
Clinical characteristics and genotypes in the ADVANCE baseline data set, a comprehensive cohort of US children and adolescents with Pompe disease.
Clinical consequences of reduced dosing schedule during treatment of a patient with Pompe's disease.
Clinical diversity in glycogenosis type II. Biosynthesis and in situ localization of acid alpha-glucosidase in mutant fibroblasts.
Clinical efficacy of the enzyme replacement therapy in patients with late-onset Pompe disease: a systematic review and a meta-analysis.
Clinical guidelines for late-onset Pompe disease.
Clinical manifestation and natural course of late-onset Pompe's disease in 54 Dutch patients.
Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease.
Common antigenicity for two glycosidases.
Comparative pathology of the canine model of glycogen storage disease type II (Pompe's disease).
Correcting Neuromuscular Deficits With Gene Therapy in Pompe Disease.
Correction of multiple striated muscles in murine Pompe disease through adeno-associated virus-mediated gene therapy.
Correction/mutation of acid alpha-D-glucosidase gene by modified single-stranded oligonucleotides: in vitro and in vivo studies.
Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in adult patients with Pompe disease.
Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in classic-infantile patients with Pompe disease.
Cystic fibrosis newborn screening: a model for neuromuscular disease screening?
Decreased activity of acid alpha-glucosidase in a patient with persistent periocular swelling after infusions of hydroxyethyl starch.
Desensitisation of the youngest patient with Pompe disease in response to alglucosidase alfa.
Desensitization of an adult patient with Pompe disease and a history of anaphylaxis to alglucosidase alfa.
Desensitization of two young patients with infantile-onset Pompe disease and severe reactions to alglucosidase alfa.
Detection of human acid alpha-glucosidase in fibroblasts using monoclonal antibodies in a biotin-avidin amplified ELISA.
Diagnosis and treatment of late-onset Pompe disease in the Middle East and North Africa region: consensus recommendations from an expert group.
Diagnosis of Pompe disease: muscle biopsy vs blood-based assays.
Diagnosis of Pompe's disease in cultured skin fibroblasts and primary amniotic fluid cells using 4-methylumbelliferyl-alpha-D-glucopyranoside as substrate.
Diagnosis of Pompe's disease using pyridylamino-maltooligosaccharides as substrates of alpha-1,4-glucosidase.
Differential muscular glycogen clearance after enzyme replacement therapy in a mouse model of Pompe disease.
Divergent clinical outcomes of alpha-glucosidase enzyme replacement therapy in two siblings with infantile-onset Pompe disease treated in the symptomatic or pre-symptomatic state.
Earlier and higher dosing of alglucosidase alfa improve outcomes in patients with infantile-onset Pompe disease: Evidence from real-world experiences.
Effect of enzyme replacement therapy with alglucosidase alfa (Myozyme®) in 12 patients with advanced late-onset Pompe disease.
Effects of a higher dose of alglucosidase alfa on ventilator-free survival and motor outcome in classic infantile Pompe disease: an open-label single-center study.
Effects of non-contractile inclusions on mechanical performance of skeletal muscle.
Efficacy, safety profile, and immunogenicity of alglucosidase alfa produced at the 4,000-liter scale in US children and adolescents with Pompe disease: ADVANCE, a phase IV, open-label, prospective study.
Electrocardiographic response to enzyme replacement therapy for Pompe disease.
Endolysosomal N-glycan processing is critical to attain the most active form of the enzyme acid alpha-glucosidase.
Enhanced enzyme activity after incubation with zinc can be used to distinguish heterozygotes of Pompe's disease.
Enzyme inhibitory assay using monoclonal antibody against acid alpha-D-glucosidase in prenatal diagnosis to identify homozygotes of Pompe's disease.
Enzyme replacement therapy desensitization in a child with infantile onset Pompe disease.
Enzyme replacement therapy for infantile Pompe disease during the critical period and identification of a novel mutation.
Enzyme replacement therapy for infantile-onset Pompe disease.
Enzyme replacement therapy in late-onset Pompe disease: a systematic literature review.
Enzyme replacement therapy in late-onset Pompe's disease: a three-year follow-up.
Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial.
Enzyme replacement therapy with alglucosidase alfa in a late-onset Pompe disease patient during pregnancy.
Enzyme replacement therapy with alglucosidase alfa in Pompe disease: Clinical experience with rate escalation.
Enzyme therapy for pompe disease with recombinant human alpha-glucosidase from rabbit milk.
Expression of lysosomal enzymes in human mutant fibroblast-chick erythrocyte heterokaryons.
Extended phenotype description and new molecular findings in late onset glycogen storage disease type II: a northern Italy population study and review of the literature.
First experience with enzyme replacement therapy during pregnancy and lactation in Pompe disease.
First trimester diagnosis of Pompe's disease (glycogenosis type II) with normal outcome: assay of acid alpha-glucosidase in chorionic villous biopsy using antibodies.
Four unreported types of glycans containing mannose-6-phosphate are heterogeneously attached at three sites (including newly found Asn 233) to recombinant human acid alpha-glucosidase that is the only approved treatment for Pompe disease.
Frequent mutation in Chinese patients with infantile type of GSD II in Taiwan: evidence for a founder effect.
Functional assessment tools in children with Pompe disease: A pilot comparative study to identify suitable outcome measures for the standard of care.
Generalised glycogenosis in Brahman cattle.
Generalized glycogenosis in beef shorthorn cattle--heterozygote detection.
Genetic defects in patients with glycogenosis type II (acid maltase deficiency).
Genotype-phenotype correlation in adult-onset acid maltase deficiency.
Glycogen storage disease type II (Pompe disease)--influence of enzyme replacement therapy in adults.
Glycogen storage disease type II in Israel.
Glycogen storage disease types I and II: treatment updates.
Glycogen storage diseases in animals and their potential value as models of human disease.
Glycogenosis type II (acid maltase deficiency).
Haemopoietic chimaerism: a complication in heterozygote detection tests for inherited defects in cattle.
Heterozygote detection in a family of Lapland dogs with a recessively inherited metabolic disease: canine glycogen storage disease type II.
High antibody titer in an adult with Pompe disease affects treatment with alglucosidase alfa.
High dose IVIG successfully reduces high rhGAA IgG antibody titers in a CRIM-negative infantile Pompe disease patient.
Higher dosing of alglucosidase alfa improves outcomes in children with Pompe disease: a clinical study and review of the literature.
Human lysosomal alpha-glucosidase: functional characterization of the glycosylation sites.
Hydrostatic isolated limb perfusion with adeno-associated virus vectors enhances correction of skeletal muscle in Pompe disease.
Identification of a de novo point mutation resulting in infantile form of Pompe's disease.
Identification of a small deletion in one allele of patients with infantile form of glycogen storage disease type II.
Identification of heterozygotes for glycogenosis 2 (acid maltase deficiency).
Immune Modulation Therapy in a CRIM-Positive and IgG Antibody-Positive Infant with Pompe Disease Treated with Alglucosidase Alfa: A Case Report.
Immunocytochemical analysis of normal and acid maltase-deficient muscle cultures.
Immunological challenges and approaches to immunomodulation in Pompe disease: a literature review.
Improved efficacy of a next-generation ERT in murine Pompe disease.
Improvement in Cardiac Function With Enzyme Replacement Therapy in a Patient With Infantile-Onset Pompe Disease.
Improvement of dysphagia in a child affected by Pompe disease treated with enzyme replacement therapy.
Improvement with ongoing Enzyme Replacement Therapy in advanced late-onset Pompe disease: a case study.
Infantile-onset Pompe disease: Diagnosis and management.
Inhibition of alpha-glucosidase in cattle by Castanospermum australe: an attempted phenocopy of Pompe's disease.
Inhibition of bovine alpha-glucosidase by Castanospermum australe and its effect on the biochemical identification of heterozygotes for generalised glycogenosis type II (Pompe's disease) in cattle.
Inhibitory effect of phloroglucinol on ?-glucosidase: Kinetics and molecular dynamics simulation integration study.
Late-onset acid maltase deficiency. Biochemical studies of leukocytes.
Late-onset Glycogen Storage Disease type 2.
Late-Onset Glycogen Storage Disease Type II (Pompe's Disease) with a Novel Mutation: A Malaysian Experience.
Late-Onset Pompe Disease with Nemaline Bodies.
Lentiviral gene therapy of murine hematopoietic stem cells ameliorates the Pompe disease phenotype.
Letter to the Editors: Concerning "Divergent clinical outcomes of alpha-glucosidase enzyme replacement therapy in two siblings with infantile-onset Pompe disease treated in the symptomatic or pre-symptomatic state" by Takashi et al. and Letter to the Editors by Ortolano et al.
Long-term benefit of enzyme replacement therapy with alglucosidase alfa in adults with Pompe disease: Prospective analysis from the French Pompe Registry.
Long-term enzyme replacement therapy for pompe disease with recombinant human alpha-glucosidase derived from chinese hamster ovary cells.
Long-term enzyme-replacement therapy (ERT) with alglucosidase alfa: Evolution of two siblings with juvenile late-onset Pompe disease.
Long-term exposure to Myozyme results in a decrease of anti-drug antibodies in late-onset Pompe disease patients.
Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk.
Long-Term Observation of the Safety and Effectiveness of Enzyme Replacement Therapy in Japanese Patients with Pompe Disease: Results From the Post-marketing Surveillance.
Looking for protein stabilizing drugs with thermal shift assay.
Lymphocyte alpha-glucosidase in late-onset glycogenosis type II.
Lysosomal glycogen storage mimicking the cytological picture of Pompe's disease as induced in rats by injection of an alpha-glucosidase inhibitor. I. Alterations in liver.
Lysosomal storage diseases.
Lysosomal storage of glycogen as a sequel of alpha-glucosidase inhibition by the absorbed deoxynojirimycin derivative emiglitate (BAYo1248). A drug-induced pattern of hepatic glycogen storage mimicking Pompe's disease (glycogenosis type II).
Management of Confirmed Newborn-Screened Patients With Pompe Disease Across the Disease Spectrum.
Molecular diagnosis of German patients with late-onset glycogen storage disease type II.
Molecular Diagnosis of Pompe Disease in the Genomic Era: Correlation with Acid Alpha-Glucosidase Activity in Dried Blood Spots.
Molecular study on the infantile form of Pompe disease in Chinese in Taiwan.
Monitoring cardiac function by B-type natriuretic peptide (BNP) in patients with infantile Pompe's disease treated with recombinant alpha-glucosidase.
Morphological changes in muscle tissue of patients with infantile Pompe's disease receiving enzyme replacement therapy.
Multiple neutral maltase activities in normal and acid maltase-deficient human muscle.
Muscle biopsy in Pompe disease.
Muscle Proteomic Profile before and after Enzyme Replacement Therapy in Late-Onset Pompe Disease.
Nephrotic syndrome complicating alpha-glucosidase replacement therapy for Pompe disease.
New insights into therapeutic options for Pompe disease.
New kind of cytoplasmic inclusions of plasma cells in acid maltase deficiency.
New therapeutic approaches for Pompe disease: enzyme replacement therapy and beyond.
Non-depleting anti-CD4 monoclonal antibody induces immune tolerance to ERT in a murine model of Pompe disease.
Nosology of lysosomal glycogen storage diseases without in vitro acid maltase deficiency. Delineation of a neonatal form.
Partial characterization of leucocyte alpha-glucosidase in late onset glycogenosis type II.
Partial phenotypic correction and immune tolerance induction to enzyme replacement therapy after hematopoietic stem cell gene transfer of alpha-glucosidase in Pompe disease.
Persistence of high sustained antibodies to enzyme replacement therapy despite extensive immunomodulatory therapy in an infant with Pompe disease: Need for agents to target antibody-secreting plasma cells.
Pharmacological Enhancement of Mutated alpha-Glucosidase Activity in Fibroblasts from Patients with Pompe Disease.
Phase I/II trial of adeno-associated virus-mediated alpha-glucosidase gene therapy to the diaphragm for chronic respiratory failure in Pompe disease: initial safety and ventilatory outcomes.
Phenotype variations in early onset Pompe disease: diagnosis and treatment results with Myozyme.
Pompe disease: a review of the current diagnosis and treatment recommendations in the era of enzyme replacement therapy.
Pompe disease: pathogenesis, molecular genetics and diagnosis.
Pompe's disease in Chinese and prenatal diagnosis by determination of alpha-glucosidase activity.
Postmortem Findings and Clinical Correlates in Individuals with Infantile-Onset Pompe Disease.
Prenatal diagnosis of Pompe disease by electron microscopy.
Prenatal diagnosis of type II glycogenosis (Pompe's disease) using microchemical analyses.
Prenatal exclusion of Pompe disease by electron microscopy.
Preparation of monoclonal antibodies against acid alpha-D-glucosidase for study of Chinese glycogenosis type II patients.
Progress in Enzyme Replacement Therapy in Glycogen Storage Disease Type II.
Properties of the alpha-glucosidase from various human tissues in relation to glycogenosis type II (Pompe's disease).
Prospective exploratory muscle biopsy, imaging, and functional assessment in patients with late-onset Pompe disease treated with alglucosidase alfa: The EMBASSY Study.
Quantitation of Alpha-Glucosidase Activity Using Fluorinated Carbohydrate Array and MALDI-TOF-MS.
Quantitative whole-body magnetic resonance imaging in children with Pompe disease: Clinical tools to evaluate severity of muscle disease.
Rapid diagnosis of late-onset Pompe disease by fluorometric assay of alpha-glucosidase activities in dried blood spots.
Reappearance of embryonic neutral alpha-glucosidase isoenzyme in acid maltase-deficient muscle of Japanese quail.
Recombinant human acid alpha-glucosidase (rhGAA) in adult patients with severe respiratory failure due to Pompe disease.
Reevaluating the pathogenicity of the mutation c.1194 +5 G>A in GAA gene by functional analysis of RNA in a 61-year-old woman diagnosed with Pompe disease by muscle biopsy.
Replacing acid alpha-glucosidase in Pompe disease: recombinant and transgenic enzymes are equipotent, but neither completely clears glycogen from type II muscle fibers.
Respiratory function during enzyme replacement therapy in late-onset Pompe disease: longitudinal course, prognostic factors, and the impact of time from diagnosis to treatment start.
Safety and efficacy of alternative alglucosidase alfa regimens in Pompe disease.
Safety of Intradiaphragmatic Delivery of Adeno-Associated Virus-Mediated Alpha-Glucosidase (rAAV1-CMV-hGAA) Gene Therapy in Children Affected by Pompe Disease.
Screening for late-onset Pompe disease in western Denmark.
Screening for Pompe disease using a rapid dried blood spot method: experience of a clinical diagnostic laboratory.
Selective vacuolar myopathy with atrophy of type II fibers. Occurrence in a childhood case of acid maltase deficiency.
Skeletal muscle pathology of infantile Pompe disease during long-term enzyme replacement therapy.
Small intestinal glucoamylase deficiency and starch malabsorption: a newly recognized alpha-glucosidase deficiency in children.
Stabilising normal and mis-sense variant alpha-glucosidase.
STIG study: real-world data of long-term outcomes of adults with Pompe disease under enzyme replacement therapy with alglucosidase alfa.
Structure of human lysosomal acid ?-glucosidase-a guide for the treatment of Pompe disease.
Subcellular distribution of acid alpha-glucosidase in fibroblasts and of antigenically cross-reactive material in Pompe's disease fibroblasts.
Successful Desensitisation in a Patient with CRIM-Positive Infantile-Onset Pompe Disease.
Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease.
Sudden deterioration in nonclassical infantile-onset Pompe disease responding to alglucosidase alfa infusion therapy: a case report.
Survival and long-term outcomes in late-onset Pompe disease following alglucosidase alfa treatment: a systematic review and meta-analysis.
Sustained immune tolerance induction in enzyme replacement therapy-treated CRIM-negative patients with infantile Pompe disease.
The bovine alpha-glucosidase gene: coding region, genomic structure, and mutations that cause bovine generalized glycogenosis.
The change in the pH 4 and pH 6 forms of alpha-glucosidase in cultured amniotic fluid cells and its implication in prenatal diagnosis of Pompe's disease.
The electrophoretic pattern and activities of acid and neutral maltase of cultivated fibroblasts and amniotic fluid cells from controls and patients with the variant of glycogen storage disease type II (Pompe's disease).
The emerging phenotype of long-term survivors with infantile Pompe disease.
The endocrine glands in Pompe's disease. Report of two cases.
The impact of Pompe disease on smooth muscle: a review.
The new era of Pompe disease: advances in the detection, understanding of the phenotypic spectrum, pathophysiology, and management.
The Pharmacological Chaperone AT2220 Increases Recombinant Human Acid ?-Glucosidase Uptake and Glycogen Reduction in a Mouse Model of Pompe Disease.
The spectrum of myotonic and myopathic disorders in a pediatric electromyography laboratory over 12 years.
The use of acarbose inhibition in the measurement of acid alpha-glucosidase activity in blood lymphocytes for the diagnosis of Pompe disease.
Therapeutic approaches in glycogen storage disease type II/Pompe Disease.
Three patients with glycogen storage disease type II and the mutational spectrum of GAA in Korean patients.
Tissue alpha-glucosidase activity and glycogen content in patients with generalized glycogenosis.
Treatment of acid maltase deficiency with a diet high in branched-chain amino acids.
Tris discriminates between the different alpha-glucosidase activities from extracts of human neutrophils.
Two alpha-glucosidases in cultured amniotic fluid cells and their differentiation in the prenatal diagnosis of Pompe's disease.
Two cases of Pompe's disease: case report and review of literature.
Two extremes of the clinical spectrum of glycogen storage disease type II in one family: a matter of genotype.
Two successfully completed pregnancies in adult onset Pompe disease, under continued treatment with alglucosidase alfa.
Urinary alpha-glucosidase analysis for the detection of the adult form of Pompe's disease.
Use of immobilized antibodies in investigating acid alpha-glucosidase in urine in relation to Pompe's disease.
Using human Pompe disease-induced pluripotent stem cell-derived neural cells to identify compounds with therapeutic potential.
White blood cells and the diagnosis of alpha-glucosidase deficiency.
Zonal differences of alpha-glucosidases in human kidney: studies in controls and in patients with glycogenosis type II.
[Adult form of Pompe disease]
[Biochemical diagnosis of glycogenosis type II (acid maltase deficiency) (author's transl)]
[Clinical, preclinical and prenatal diagnosis of congenital sphingolipidoses by determining lysosomal hydrolases (author's transl)]
[Enzyme replacement therapies for lysosomal storage disorders.]
[Enzyme replacement therapy in Pompe's disease]
[Guidelines for monitoring late-onset Pompe disease.Sociedad Española de Medicina Interna (SEMI), Sociedad Española de Neurología (SEN) y Sociedad Española de Neumología y CirugíaTorácica (SEPAR)].
[Late infantile form of Pompe's disease. Deficiency of alpha-1,4-glucosidase (acid maltase)]
[Pompe and his disease].
[Tests for the detection of inborn errors of metabolism--urinary alpha-glucosidase analysis for the detection of glycogen storage disease type II (author's transl)]
Glycogen Storage Disease Type III
Alglucosidase alfa enzyme replacement therapy as a therapeutic approach for glycogen storage disease type III.
Glycogen Storage Disease Type IV
Acid maltase deficiency and related myopathies.
Alglucosidase alfa treatment alleviates liver disease in a mouse model of glycogen storage disease type IV.
Glycosuria
Effect of the alpha-glucosidase inhibitor Bay-O-1248 on the metabolic response of nondiabetic and diabetic rats to a high-carbohydrate diet.
Reversal of abnormal retinal hemodynamics in diabetic rats by acarbose, an alpha-glucosidase inhibitor.
Heart Block
Complete heart block with myocardial membrane-bound glycogen and normal peripheral alpha-glucosidase activity.
Heart Failure
Alpha-glucosidase inhibitors: new therapeutic agents for chronic heart failure.
Control of plasma glucose with alpha-glucosidase inhibitor attenuates oxidative stress and slows the progression of heart failure in mice.
Correction: The effect of luseogliflozin and alpha-glucosidase inhibitor on heart failure with preserved ejection fraction in diabetic patients: rationale and design of the MUSCAT-HF randomised controlled trial.
Risk of hospitalization for heart failure associated with thiazolidinedione therapy: a medicaid claims-based case-control study.
The effect of luseogliflozin and alpha-glucosidase inhibitor on heart failure with preserved ejection fraction in diabetic patients: rationale and design of the MUSCAT-HF randomised controlled trial.
Hemorrhagic Stroke
[The association between plasma neurotransmitters levels and depression in acute hemorrhagic stroke].
Hepatitis
Activity of alpha-1,4-glucosidase in extrahepatic cholestasis and acute viral hepatitis.
Serum beta-N-acetylglucosaminidase, beta-D-glucosidase, alpha-D-glucosidase, beta-D-fucosidase, alpha-L-fucosidase and beta-D-galactosidase levels in acute viral hepatitis, pancreatitis, myocardial infarction and breast cancer.
Hepatitis B
Aberrant trafficking of hepatitis B virus glycoproteins in cells in which N-glycan processing is inhibited.
Adding to the hepatitis B virus treatment arsenal: alpha-glucosidase inhibitor derivatives.
alpha-Glucosidase inhibitors have a prolonged antiviral effect against hepatitis B virus through the sustained inhibition of the large and middle envelope glycoproteins.
Treatment of hepatitis B virus-infected cells with alpha-glucosidase inhibitors results in production of virions with altered molecular composition and infectivity.
Hepatitis C
Reduction of the infectivity of hepatitis C virus pseudoparticles by incorporation of misfolded glycoproteins induced by glucosidase inhibitors.
Herpes Simplex
The effect of oral treatment with 6-O-butanoyl castanospermine (MDL 28,574) in the murine zosteriform model of HSV-1 infection.
Herpes Zoster
Relationship between semen characteristics, alpha-glucosidase and the capacity of spermatozoa to bind to the human zona pellucida.
HIV Infections
A novel lectin from Pseudostellaria heterophylla roots with sequence simularity to Kunitz-type soybean trypsin inhibitor.
Hypogin, a novel antifungal peptide from peanuts with sequence similarity to peanut allergen.
Structurally dissimilar proteins with antiviral and antifungal potency from cowpea (Vigna unguiculata) seeds.
Huntington Disease
Loss of endoplasmic reticulum-associated enzymes in affected brain regions in Huntington's disease and Alzheimer-type dementia.
Hydronephrosis
[Neutral alpha-glucosidase activity in the urine in congenital hydronephrosis in children]
Hypercholesterolemia
Anti-hyperglycemic and anti-hyperlipidemic effects of guava leaf extract.
Blood glucose-lowering activity of colestimide in patients with type 2 diabetes and hypercholesterolemia: a case-control study comparing colestimide with acarbose.
Hyperglycemia
A pilot study of the efficacy of miglitol and sitagliptin for type 2diabetes with a continuous glucose monitoring system and incretin-related markers.
A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44)
A review of alpha-glucosidase inhibitors from plants as potential candidates for the treatment of type-2 diabetes.
A series of cinnamic acid derivatives and their inhibitory activity on intestinal alpha-glucosidase.
Acarbose is a promising therapeutic strategy for the treatment of patients with nonalcoholic steatohepatitis (NASH).
Acarbose partially prevents the development of diabetes mellitus by multiple low-dose streptozotocin administration.
Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial.
Acarbose treatments improve arterial stiffness in patients with type 2 diabetes mellitus.
Acarbose, an alpha-glucosidase inhibitor, improves insulin resistance in fructose-fed rats.
Alleviating the Hydrolysis of Carbohydrates, Tangzhiqing (TZQ) Decreased the Postprandial Glycemia in Healthy Volunteers: An Eight-Period Crossover Study.
alpha-Glucosidase inhibition improves postprandial hyperglycemia and decreases insulin requirements in insulin-dependent diabetes mellitus.
alpha-Glucosidase inhibitors prevent diet-induced increases in intestinal sugar transport in diabetic mice.
Alpha-glucosidase inhibitory activity of a 70% methanol extract from ezoishige (Pelvetia babingtonii de Toni) and its effect on the elevation of blood glucose level in rats.
Altered expression of muscle glucose transporter GLUT-4 in diabetic fatty Zucker rats (ZDF/Drt-fa).
An alpha-glucosidase inhibitor, AO-128, retards carbohydrate absorption in rats and humans.
Anti-diabetic and anti-hypertensive potential of sprouted and solid-state bioprocessed soybean.
Anti-hyperglycemic and anti-hyperlipidemic effects of guava leaf extract.
Antioxidant rich grape pomace extract suppresses postprandial hyperglycemia in diabetic mice by specifically inhibiting alpha-glucosidase.
Biological interaction of newly synthesized astaxanthin-s-allyl cysteine biconjugate with Saccharomyces cerevisiae and mammalian ?-glucosidase: In vitro kinetics and in silico docking analysis.
Changes in alpha-glucosidase activities along the jejunal-ileal axis of normal rats by the alpha-glucosidase inhibitor miglitol.
Clinical utility of acarbose, an alpha-glucosidase inhibitor in cardiometabolic disorders.
Comparison of efficacies of a dipeptidyl peptidase IV inhibitor and alpha-glucosidase inhibitors in oral carbohydrate and meal tolerance tests and the effects of their combination in mice.
Control of post-prandial hyperglycemia--an essential part of good diabetes treatment and prevention of cardiovascular complications.
Critical evaluation of the role of acarbose in the treatment of diabetes: patient considerations.
Current treatment approaches to type 2 diabetes mellitus: successes and shortcomings.
Dieckol isolated from Ecklonia cava inhibits alpha-glucosidase and alpha-amylase in vitro and alleviates postprandial hyperglycemia in streptozotocin-induced diabetic mice.
Diphlorethohydroxycarmalol isolated from Ishige okamurae, a brown algae, a potent alpha-glucosidase and alpha-amylase inhibitor, alleviates postprandial hyperglycemia in diabetic mice.
Effect of lipid extracts of Nigella sativa L. seeds on the liver ATP reduction and alpha-glucosidase inhibition.
Effect of two alpha-glucosidase inhibitors, voglibose and acarbose, on postprandial hyperglycemia correlates with subjective abdominal symptoms.
Effects of diabetes and hyperglycemia on disaccharidase activities in the rat.
Efficacy and safety of miglitol- or repaglinide-based combination therapy with alogliptin in drug-naïve patients with type 2 diabetes: An open-label, single-center, parallel, randomized control pilot study.
Elevated serum levels of interleukin-18 in patients with overt diabetic nephropathy: effects of miglitol.
Enzymes inhibitors from natural sources with antidiabetic activity: A review.
Evaluation of antihyperglycemia and antihypertension potential of native Peruvian fruits using in vitro models.
Experimental treatment of complications in alloxan diabetic rats with alpha-glucosidase inhibitor from the Chinese medicinal herb ramulus mori.
Extracts of Momordica charantia suppress postprandial hyperglycemia in rats.
Functionality of bioactive compounds in Brazilian strawberry (Fragaria x ananassa Duch.) cultivars: evaluation of hyperglycemia and hypertension potential using in vitro models.
In Vitro Alpha-Amylase and Alpha-Glucosidase Inhibitory Activity and In Vivo Antidiabetic Activity of Withania frutescens L. Foliar Extract.
In vitro inhibitory effects of plant-based foods and their combinations on intestinal ¿-glucosidase and pancreatic ¿-amylase.
Inhibition of alpha-glucosidase and amylase by luteolin, a flavonoid.
Inhibition of alpha-glucosidase by aqueous extracts of some potent antidiabetic medicinal herbs.
Inhibition of glucose absorption in the rat jejunum: a novel action of alpha-D-glucosidase inhibitors.
Inhibition of intestinal alpha-glucosidase and postprandial hyperglycemia by N-substituted moranoline derivatives.
Inhibition of postprandial hyperglycemia by acarbose is a promising therapeutic strategy for the treatment of patients with the metabolic syndrome.
Inhibitory activity of Euonymus alatus against alpha-glucosidase in vitro and in vivo.
Inhibitory effect of Azadirachta indica A. juss leaf extract on the activities of alpha-amylase and alpha-glucosidase.
Inhibitory effect of koji Aspergillus terreus on alpha-glucosidase activity and postprandial hyperglycemia.
Inhibitory effect of methanol extract of Rosa damascena Mill. flowers on alpha-glucosidase activity and postprandial hyperglycemia in normal and diabetic rats.
Inhibitory effect of pine extract on alpha-glucosidase activity and postprandial hyperglycemia.
Inhibitory effects of hyssop (Hyssopus officinalis) extracts on intestinal alpha-glucosidase activity and postprandial hyperglycemia.
Insulin releasing and alpha-glucosidase inhibitory activity of ethyl acetate fraction of Acorus calamus in vitro and in vivo.
Intestinal alpha-glucosidase inhibitory activity and toxicological evaluation of Nymphaea stellata flowers extract.
Miglitol improves postprandial endothelial dysfunction in patients with acute coronary syndrome and new-onset postprandial hyperglycemia.
Miglitol prevents diet-induced obesity by stimulating brown adipose tissue and energy expenditure independent of preventing the digestion of carbohydrates.
Miglitol protects against age-dependent weight gain in mice: A potential role of increased UCP1 content in brown adipose tissue.
Miglitol suppresses the postprandial increase in interleukin 6 and enhances active glucagon-like peptide 1 secretion in viscerally obese subjects.
New developments in type 2 diabetes mellitus: combination therapy with a thiazolidinedione.
Plasma glycohydrolase levels in patients with type 1 diabetes at onset and in subjects undergoing an intravenous glucose tolerance test.
Postprandial hyperglycemia: implications for practice.
Potent alpha-glucosidase inhibitors purified from the red alga Grateloupia elliptica.
Punica granatum flower extract, a potent alpha-glucosidase inhibitor, improves postprandial hyperglycemia in Zucker diabetic fatty rats.
Reduction of postprandial hyperglycemia in patients with type 2 diabetes reduces NF-kappaB activation in PBMCs.
Relationship between gastric emptying and an alpha-glucosidase inhibitor effect on postprandial hyperglycemia in NIDDM patients.
Repetitive postprandial hyperglycemia increases cardiac ischemia/reperfusion injury: prevention by the alpha-glucosidase inhibitor acarbose.
Salacia oblonga improves cardiac fibrosis and inhibits postprandial hyperglycemia in obese Zucker rats.
Screening alpha-glucosidase and alpha-amylase inhibitors from natural compounds by molecular docking in silico.
Single administration of alpha-glucosidase inhibitors on endothelial function and incretin secretion in diabetic patients with coronary artery disease - Juntendo University trial: effects of miglitol on endothelial vascular reactivity in type 2 diabetic patients with coronary heart disease (J-MACH) -.
Synthesis and alpha-glucosidase-inhibiting activity of a new alpha-glucosidase inhibitor, 4-O-alpha-D-glucopyranosylmoranoline and its N-substituted derivatives.
The alpha-glucosidase inhibitor acarbose prevents obesity and simple steatosis in sequestosome 1/A170/p62 deficient mice.
The alpha-glucosidase inhibitor miglitol affects bile acid metabolism and ameliorates obesity and insulin resistance in diabetic mice.
The alpha-glucosidase inhibitor miglitol decreases glucose fluctuations and gene expression of inflammatory cytokines induced by hyperglycemia in peripheral leukocytes.
Treating dual defects in diabetes: insulin resistance and insulin secretion.
Treatment of type 2 diabetes mellitus in children and adolescents.
Treatment with acarbose may improve endothelial dysfunction in streptozotocin-induced diabetic rats.
Voglibose (Basen, AO-128), one of the most important alpha-glucosidase inhibitors.
Voglibose potentiates the hepatotoxicity of carbon tetrachloride and acetaminophen by inducing CYP2E1 in rats.
Who should benefit from the use of alpha-glucosidase inhibitors?
[Current evidence on the early intervention of diabetes]
[Development of alpha-glucosidase inhibitor from medicinal herbs]
[Exploring an optimal approach to the use of oral hypoglycemic agents based on CGM results: implications for combination therapy with oral hypoglycemic agents].
[Hypoglycemia in the diabetes treatment - risk minimization with dipeptidyl peptidase-4 inhibitors].
[Occurrence of ileus after voglibose treatment in an elderly diabetic patient with gait disturbance caused by cerebral hemorrhage]
[Study on the inhibition of alpha-glucosidase by soyasaponins]
[The clinical significance of early intervention for impaired glucose tolerance]
[Valibose, an alpha-glucosidase inhibitor, ameliorates the metabolic disorder of glucose and lipids and the nephropathy in streptozotocin-induced diabetic rats].
Hyperinsulinism
An alpha-glucosidase inhibitor, AO-128, retards carbohydrate absorption in rats and humans.
Anti-hyperglycemic and anti-hyperlipidemic effects of guava leaf extract.
Cardiovascular disease in the JCR:LA-cp rat.
Effects of acarbose in beta-thalassaemia major patients with normal glucose tolerance and hyperinsulinism.
Hypokalemic periodic paralysis in a patient with acquired growth hormone deficiency.
Voglibose (Basen, AO-128), one of the most important alpha-glucosidase inhibitors.
Hyperlipidemias
Inhibitory effects of estrogens on digestive enzymes, insulin deficiency, and pancreas toxicity in diabetic rats.
Hyperlipoproteinemia Type II
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2019 EXECUTIVE SUMMARY.
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2020 EXECUTIVE SUMMARY.
Hypertension
Acarbose is a promising therapeutic strategy for the treatment of patients with nonalcoholic steatohepatitis (NASH).
Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial.
Alpha-glucosidase inhibitors 2012 - cardiovascular considerations and trial evaluation.
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2017 EXECUTIVE SUMMARY.
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2018 EXECUTIVE SUMMARY.
Evaluation of antihyperglycemia and antihypertension potential of native Peruvian fruits using in vitro models.
Evaluation of urinary enzyme patterns in patients with kidney diseases and primary benign hypertension.
Functionality of bioactive compounds in Brazilian strawberry (Fragaria x ananassa Duch.) cultivars: evaluation of hyperglycemia and hypertension potential using in vitro models.
Modulation of circulating vasoactive peptides and extracellular matrix proteins are two novel mechanisms in the cardioprotective action of acarbose.
Phenolic-linked variation in strawberry cultivars for potential dietary management of hyperglycemia and related complications of hypertension.
Pioglitazone produces rapid and persistent reduction of vascular inflammation in patients with hypertension and type 2 diabetes mellitus who are receiving angiotensin II receptor blockers.
Potential of Ginkgo biloba L. leaves in the management of hyperglycemia and hypertension using in vitro models.
Systemic medications and cortical cataract: the Singapore Epidemiology of Eye Diseases Study.
Hyperthyroidism
Serum lysosomal acid hydrolase activities in Graves' disease.
Hypertriglyceridemia
Reduction of carbohydrate-induced hypertriglyceridemia in (fa,fa) "Zucker" rats by the alpha-glucosidase inhibitor acarbose (BAY g 5421).
Hypervitaminosis A
Effect of hypervitaminosis A on intestinal digestive & absorptive functions in rat.
Hypoglycemia
A new approach to the treatment of nocturnal hypoglycemia using alpha-glucosidase inhibition.
Advantages of alpha-glucosidase inhibition as monotherapy in elderly type 2 diabetic patients.
Antidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis: metabolism and clinical practice.
Comparison of antidiabetic drugs added to sulfonylurea monotherapy in patients with type 2 diabetes mellitus: A network meta-analysis.
Concurrent Therapy with a Low-carbohydrate Diet and Miglitol Remarkably Improved the Postprandial Blood Glucose and Insulin Levels in a Patient with Reactive Hypoglycemia due to Late Dumping Syndrome.
Emergence of promising novel DPP-4 inhibitory heterocycles as anti-diabetic agents: A review.
Incretin-based therapies in the management of type 2 diabetes: rationale and reality in a managed care setting.
Nateglinide is Effective for Diabetes Mellitus with Reactive Hypoglycemia in a Child with a Compound Heterozygous ABCC8 Mutation.
Pioglitazone prevents reactive hypoglycemia in impaired glucose tolerance.
Postprandial Reactive Hypoglycemia Treated with a Low-dose Alpha-glucosidase Inhibitor: Voglibose May Suppress Oxidative Stress and Prevent Endothelial Dysfunction.
Safety, tolerability and efficacy of lixisenatide in combination with oral antidiabetic treatment in Japanese patients with type 2 diabetes: An open-label, multicenter study.
Treatment with alpha-glucosidase inhibitor for severe reactive hypoglycemia: a case report.
Use of the alpha glucosidase inhibitor acarbose in patients with 'Middleton syndrome': normal gastric anatomy but with accelerated gastric emptying causing postprandial reactive hypoglycemia and diarrhea.
[Alpha-glucosidase inhibitors: a new therapeutic approach in diabetes and functional hypoglycemia]
[Evaluation of the association between the use of oral anti-hyperglycemic agents and hypoglycemia in Japan by data mining of the Japanese Adverse Drug Event Report (JADER) database].
Hypotension
Acarbose, an alpha-glucosidase inhibitor, attenuates postprandial hypotension in autonomic failure.
[A case of hemodynamic brain infarction with postprandial hypotension]
Hypothyroidism
Relative importance of corticosterone and thyroxine in the postnatal development of sucrase and maltase in rat small intestine.
Ileus
Ileus after administration of cold remedy in an elderly diabetic patient treated with acarbose.
Infections
A high-throughput assay using dengue-1 virus-like particles for drug discovery.
Antiviral effect of {alpha}-glucosidase inhibitors on viral morphogenesis and binding properties of hepatitis C virus-like particles.
Astrovirus infection in hatchling turkeys: alterations in intestinal maltase activity.
Biochemical analysis of jejunal brush border membrane of golden hamster: pathogenic modulations due to ancylostomiasis.
Castanospermine, a potent inhibitor of dengue virus infection in vitro and in vivo.
Changes in the intestinal enzyme activity of lambs during chronic infection with Trichostrongylus vitrinus.
Comparative development of Brugia pahangi and variation in acid hydrolase enzyme titers in.
Content of saccharides and activity of alpha-glycosidases in Galleria mellonella larvae infected with entomopathogenic nematodes Heterorhabditis zealandica.
Diagnostic potential of urinary enzymes and beta 2-microglobulin in acute urinary tract infection.
Disaccharidase activity in male and female C57BL/6 mice infected with Giardia muris.
Disaccharidase activity in the small intestine of susceptible and resistant mice after primary and challenge infections with Giardia muris.
Disaccharidase deficiencies in Mongolian gerbils (Meriones unguiculatus) protected against Giardia lamblia.
Impact of infection on the secretory capacity of the male accessory glands.
Intestinal enzyme profiles in normal and rotavirus-infected mice.
[Automatic detection and clinical application of semen biochemical markers].
[Study of lysosomal enzymes in chick embryo fibroblasts infected with microorganisms of family Halprowiaceae (Chlamydiaceae)]
[Ureaplasma urealyticum infection in the genital tract reduces seminal quality in infertile men]
Infertility
Approaches to post-testicular contraception.
Correlation between neutral alpha-glucosidase activity and sperm DNA fragmentation.
Epididymal markers in human infertility.
New discriminatory level for glucosidase activity to diagnose epididymal obstruction or dysfunction.
Origin of maltase and variations in infertile men.
Seminal alpha-glucosidase activity as a marker of epididymal pathology in nonazoospermic men consulting for infertility.
The value of semen characteristics and tests of sperm function in selecting couples for intra-uterine insemination.
Why do we determine alpha-glucosidase activity in human semen during infertility work-up?
[Changes in the enzyme level of the sperm of men with infertility]
Infertility, Male
Seminal plasma alpha-glucosidase activity and male infertility.
Seminal Plasma Analysis of Oxidative Stress in Different Genitourinary Topographical Regions Involved in Reproductive Tract Disorders Associated with Genital Heat Stress.
Inflammatory Bowel Diseases
Subcellular fractionation of rectal biopsy homogenates from patients with inflammatory bowel disease.
The role of probiotic cultures in the control of gastrointestinal health.
Influenza, Human
Gateways to clinical trials.
Inhibition of mouse liver sialidase by plant flavonoids.
On the role of oligosaccharide trimming in the maturation of Sindbis and influenza virus.
Insulin Resistance
A rational approach to drug therapy of type 2 diabetes mellitus.
Acarbose treatment increases serum total adiponectin levels in patients with type 2 diabetes.
Acarbose, an alpha-glucosidase inhibitor, improves insulin resistance in fructose-fed rats.
Current therapies and emerging targets for the treatment of diabetes.
Does suppression of postprandial blood glucose excursions by the alpha-glucosidase inhibitor miglitol improve insulin sensitivity in diet-treated type II diabetic patients?
Effect of acarbose on insulin sensitivity in elderly patients with diabetes.
Effect of pioglitazone on muscle sympathetic nerve activity in type 2 diabetes mellitus with alpha-glucosidase inhibitor.
Effects of 8-wk alpha-glucosidase inhibition on metabolic control, C-peptide secretion, hepatic glucose output, and peripheral insulin sensitivity in poorly controlled type II diabetic patients.
Effects of voglibose on glycemic excursions, insulin secretion, and insulin sensitivity in non-insulin-treated NIDDM patients.
How should postprandial glycemia be treated?
Hypoglycemic and hypolipidemic effects of samnamul (shoot of Aruncus dioicus var. kamtschaticus Hara) in mice fed a high-fat/high-sucrose diet.
Hypokalemic periodic paralysis in a patient with acquired growth hormone deficiency.
Improvement of insulin sensitivity and dyslipidemia with a new alpha-glucosidase inhibitor, voglibose, in nondiabetic hyperinsulinemic subjects.
Oral antidiabetic agents in type 2 diabetes.
The alpha-glucosidase inhibitor acarbose prevents obesity and simple steatosis in sequestosome 1/A170/p62 deficient mice.
The alpha-glucosidase inhibitor miglitol affects bile acid metabolism and ameliorates obesity and insulin resistance in diabetic mice.
The alpha-glucosidase inhibitor miglitol increases hepatic CYP7A1 activity in association with altered short-chain fatty acid production in the gut of obese diabetic mice.
The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance.
The pathophysiologic basis of efficacy and clinical experience with the new oral antidiabetic agents.
Treatment of type 2 diabetes mellitus in children and adolescents.
Troglitazone combination therapy in obese type 2 diabetic patients poorly controlled with alpha-glucosidase inhibitors.
[Management of diabetes during corticosteroid therapy]
[Molecular targets for new drug discovery to treat type 2 diabetes and obesity]
[Total care for patients with metabolic syndrome]
Insulinoma
A case of insulinoma following total gastrectomy--effects of an alpha-glucosidase inhibitor on suppressing GIP and GLP-1 elevations.
Intestinal Obstruction
Acute intestinal infarction or obstruction: search for better laboratory tests in an animal model.
Prenatal detection of intestinal obstructions, aneuploidy syndromes, and cystic fibrosis by microvillar enzyme assays (disaccharidases, alkaline phosphatase, and glutamyltransferase) in amniotic fluid.
Intestinal Pseudo-Obstruction
Paralytic ileus accompanied by pneumatosis cystoides intestinalis after acarbose treatment in an elderly diabetic patient with a history of heavy intake of maltitol.
Intestinal Volvulus
Correction to: Pneumatosis cystoides intestinalis induced by the alpha-glucosidase inhibitor complicated from sigmoid volvulus in a diabetic patient.
Pneumatosis cystoides intestinalis induced by the alpha-glucosidase inhibitor complicated from sigmoid volvulus in a diabetic patient.
Intracranial Aneurysm
Alpha-glucosidase deficiency and basilar artery aneurysm: report of a sibship.
Irritable Bowel Syndrome
The role of probiotic cultures in the control of gastrointestinal health.
Kidney Diseases
Antidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis: metabolism and clinical practice.
[Neutral alpha glucosidase in human urine as a marker of kidney impairment]
[Soluble and membrane-bound forms of neutral alpha-glucosidase in human urine in normal conditions and in kidney diseases]
[Urinary excretion of alpha-glucosidase in various kidney diseases]
Kidney Neoplasms
The Antidiabetic Agent Acarbose Improves Anti-PD-1 and Rapamycin Efficacy in Preclinical Renal Cancer.
Kwashiorkor
Moderate and severe protein energy malnutrition in childhood: effects on jejunal mucosal morphology and disaccharidase activities.
lactase deficiency
Disaccharidase activity in children undergoing esophagogastroduodenoscopy: A systematic review.
Mucosal abnormalities in microsporidiosis.
Patients with functional bowel disorder have disaccharidase deficiency: A single-center study from Russia.
Selective alteration of brush-border hydrolases in intestinal diseases in childhood.
[Disaccharidase deficiency and functional bowel diseases].
Lactose Intolerance
Evaluation of differential disaccharide excretion in urine for non-invasive investigation of altered intestinal disaccharidase activity caused by alpha-glucosidase inhibition, primary hypolactasia, and coeliac disease.
The role of probiotic cultures in the control of gastrointestinal health.
[Current problems of lactase deficiency]
Leprosy, Lepromatous
Urinary excretion of renal brush-border enzymes in lepromatous leprosy--a preliminary investigation.
Leukemia
Neutral maltase: the first human B-cell enzymatic marker reflecting terminal differentiation of mature B cells into plasma cells.
Serum and host liver activities of glycosidases and sialyltransferases in animals bearing transplantable tumors.
Leukemia, Lymphoid
Neutral maltase: the first human B-cell enzymatic marker reflecting terminal differentiation of mature B cells into plasma cells.
Leukodystrophy, Metachromatic
[Clinical, preclinical and prenatal diagnosis of congenital sphingolipidoses by determining lysosomal hydrolases (author's transl)]
Liver Cirrhosis
Effects of a late evening snack combined with alpha-glucosidase inhibitor on liver cirrhosis.
Evaluation of renal tubular damage in liver cirrhosis by urinary enzymes and beta-2-microglobulin excretions.
[Non-insulin-dependent diabetes mellitus associated with nonalcoholic liver cirrhosis: an evaluation of treatment with the intestinal alpha-glucosidase inhibitor acarbose]
Liver Diseases
Alglucosidase alfa treatment alleviates liver disease in a mouse model of glycogen storage disease type IV.
alpha-Glucosidase inhibitor acarbose and sequestome 1/A170/p62 deficient mice: A promising therapy and unique model for non-alcoholic fatty liver disease.
Hypophosphatemia and renal tubular dysfunction in alcoholics. Are they related to liver function impairment?
Safe and effective treatment of diabetes mellitus associated with chronic liver diseases with an alpha-glucosidase inhibitor, acarbose.
Thiazolidinediones, alpha-glucosidase inhibitors, meglitinides, sulfonylureas, and hepatocellular carcinoma risk: A meta-analysis.
Lung Diseases
Serum neutral alpha-D-glucosidase from patients with cystic fibrosis and chronic pulmonary disease.
Lung Diseases, Interstitial
Pneumatosis cystoides intestinalis after alpha-glucosidase inhibitor treatment in a patient with interstitial pneumonitis.
Lupus Vasculitis, Central Nervous System
Pneumatosis cystoides intestinalis in neuropsychiatric systemic lupus erythematosus with diabetes mellitus: case report and literature review.
Lymphoma
alpha-Glucosidase II-deficient cells use endo alpha-mannosidase as a bypass route for N-linked oligosaccharide processing.
Identity of neutral alpha-glucosidase AB and the glycoprotein processing enzyme glucosidase II. Biochemical and genetic studies.
Transient expression of human neutral alpha-glucosidase AB (glucosidase II) in enzyme-deficient mouse lymphoma cells.
Lysosomal Storage Diseases
Acid alpha-glucosidase deficiency (glycogenosis type II, Pompe disease).
Malabsorption Syndromes
[L-alanyl-L-proline-dipeptidase and glycyl-L-valine-depeptidase in malabsorption syndrome]
Malnutrition
Contribution of villous atrophy to reduced intestinal maltase in infants with malnutrition.
Effect of pre- & post-weaning protein energy malnutrition on intestinal sucrase & maltase in rats.
Effect of prenatal exposure to ethanol on intestinal development of rat fetuses.
Interaction of malnutrition and difluoromethylornithine-induced intestinal mucosal damage: degree of severity and subsequent recovery.
Jejunal disaccharidases in protein energy malnutrition and recovery.
Moderate and severe protein energy malnutrition in childhood: effects on jejunal mucosal morphology and disaccharidase activities.
[The effect of malnutrition during milk feeding on the enzyme activity of the initial and final stages of carbohydrate hydrolysis in the small intestine of growing rats]
mannosyl-oligosaccharide glucosidase deficiency
A cross-sectional single-centre study on Pompe disease in 42 German patients: Molecular analysis of the GAA gene, manifestation and genotype-phenotype correlations.
Broad spectrum of Pompe disease in patients with the same c.-32-13T->G haplotype.
Characterization of the molecular defect in infantile and adult acid alpha-glucosidase deficiency fibroblasts.
Melanoma
Inhibition of experimental metastasis by enzyme inhibitors from microorganisms and plants.
Memory Disorders
Deletion mapping of the Drosophila memory mutant amnesiac.
Mesothelioma
Cytology of diffuse mesothelioma in the thorax of a horse.
Metabolic Diseases
alpha1,4-Glucosidase-albumin polymers: in vitro properties and advantages for enzyme replacement therapy.
Metabolic Syndrome
[Pharmacological treatment of postprandial hyperglycemia in hypertensive patients with type 2 diabetes mellitus]
Microsporidiosis
Mucosal abnormalities in microsporidiosis.
Mucolipidoses
Acid hydrolases in serum from patients with lysosomal disorders.
Electrophoretic analysis of glycoprotein enzymes in the sialidoses and mucolipidoses.
Mucopolysaccharidoses
Common antigenicity for two glycosidases.
Mucopolysaccharidosis I
Common antigenicity for two glycosidases.
Lysosomal storage diseases.
Mucopolysaccharidosis IV
Lysosomal storage diseases.
Muscle Weakness
Alpha-glucosidase deficiency and basilar artery aneurysm: report of a sibship.
Effects of respiratory muscle training (RMT) in children with infantile-onset Pompe disease and respiratory muscle weakness.
Genotype-phenotype correlation in adult-onset acid maltase deficiency.
Lentiviral gene therapy of murine hematopoietic stem cells ameliorates the Pompe disease phenotype.
Variable clinical features and genotype-phenotype correlations in 18 patients with late-onset Pompe disease.
Muscular Atrophy, Spinal
Cystic fibrosis newborn screening: a model for neuromuscular disease screening?
Muscular Diseases
Abnormal mannose-6-phosphate receptor trafficking impairs recombinant alpha-glucosidase uptake in Pompe disease fibroblasts.
Acid maltase deficiency and related myopathies.
Adult maltase acid deficiency myopathy: treatment with long-term home mechanical ventilation.
An individually, modified approach to desensitize infants and young children with Pompe disease, and significant reactions to alglucosidase alfa infusions.
Clinical consequences of reduced dosing schedule during treatment of a patient with Pompe's disease.
Clinical manifestation and natural course of late-onset Pompe's disease in 54 Dutch patients.
Effect of enzyme replacement therapy (ERT) added to Home Mechanical Ventilation (HMV) in Adult Pompe disease.
Effects of non-contractile inclusions on mechanical performance of skeletal muscle.
Improvement of dysphagia in a child affected by Pompe disease treated with enzyme replacement therapy.
New insights into therapeutic options for Pompe disease.
Pharmacological Enhancement of Mutated alpha-Glucosidase Activity in Fibroblasts from Patients with Pompe Disease.
Reduced muscle alpha-glucosidase (acid-maltase) activity in hypothyroid myopathy.
Screening for late-onset Pompe disease in western Denmark.
Selective vacuolar myopathy with atrophy of type II fibers. Occurrence in a childhood case of acid maltase deficiency.
Sleep-related obstructive and nonobstructive apneas and neurologic disorders.
The spectrum of myotonic and myopathic disorders in a pediatric electromyography laboratory over 12 years.
Vacuolar myopathy with type 2 A fiber atrophy and type 2 B fiber deficiency. A case of childhood form acid alpha-1,4-glucosidase deficiency.
Muscular Dystrophy, Duchenne
Cystic fibrosis newborn screening: a model for neuromuscular disease screening?
Myalgia
A case of adult Pompe disease presenting with severe fatigue and selective involvement of type 1 muscle fibers.
Myocardial Infarction
Combination of miglitol, an anti-diabetic drug, and nicorandil markedly reduces myocardial infarct size through opening the mitochondrial K(ATP) channels in rabbits.
Combination of N-methyl-1-deoxynojirimycin and ischemic preconditioning markedly reduces the size of myocardial infarcts in rabbits.
Does Treatment of Impaired Glucose Tolerance Improve Cardiovascular Outcomes in Patients with Previous Myocardial Infarction?
Influence of isoproterenol-induced myocardial infarction on certain glycohydrolases and cathepsins in rats.
Plasma BNP Levels and Diuretics Use as Predictors of Cardiovascular Events in Patients with Myocardial Infarction and Impaired Glucose Tolerance.
Serum beta-N-acetylglucosaminidase, beta-D-glucosidase, alpha-D-glucosidase, beta-D-fucosidase, alpha-L-fucosidase and beta-D-galactosidase levels in acute viral hepatitis, pancreatitis, myocardial infarction and breast cancer.
Myotonia Congenita
The spectrum of myotonic and myopathic disorders in a pediatric electromyography laboratory over 12 years.
Myotonic Disorders
The spectrum of myotonic and myopathic disorders in a pediatric electromyography laboratory over 12 years.
Myotonic Dystrophy
Sleep-related obstructive and nonobstructive apneas and neurologic disorders.
Neoplasm Metastasis
Inhibition of experimental metastasis by an alpha-glucosidase inhibitor, 1,6-epi-cyclophellitol.
Inhibition of experimental metastasis by enzyme inhibitors from microorganisms and plants.
Neoplasms
A new 26-norlanostane from Phlogacanthus turgidus growing in Vietnam.
Activity of alpha-1,4-glucosidase in serum from patients with malignant tumor.
Activity of glycogen depolymerizing enzymes in extracts from brain tumor tissue (anaplastic astrocytoma and glioblastoma multiforme).
Alpha-glucosidase inhibitor use is associated with decreased colorectal neoplasia risk in patients with type 2 diabetes mellitus receiving colonoscopy: a retrospective study.
Alpha-glucosidase inhibitors and risk of cancer in patients with diabetes mellitus: a systematic review and meta-analysis.
Antioxidant, cytotoxic and alpha-glucosidase inhibition activities from the Mexican berry "Anacahuita" (Cordia boissieri).
Changes in the activities of jejunal glucosidases in experimental intestinal tumorigenesis induced by 1,2 dimethylhydrazine in rats fed different diets.
Cytological and biochemical methods for the characterization of in vitro cultured cells.
Diabetes drugs and the incidence of solid cancers: a survey of the current evidence.
Differential proteome analysis of replicative senescence in rat embryo fibroblasts.
Effect of incretin-based therapies on cancers of digestive system among 101 595 patients with type 2 diabetes mellitus: a systematic review and network meta-analysis combining 84 trials with a median duration of 30 weeks.
Expression and different polarity of aminopeptidase N in normal human colonic mucosa and colonic tumors.
Flow cytometric technique for determination of prostasomal quantity, size and expression of CD10, CD13, CD26 and CD59 in human seminal plasma.
Inhibition of experimental metastasis by an alpha-glucosidase inhibitor, 1,6-epi-cyclophellitol.
Pancreatic secretory abnormalities precede appearance of tumors of the pancreas in hamsters treated with bis-(2-oxopropyl)-N-nitrosamine.
Pharmacokinetic studies on 1-(2-chloroethyl)-3-isobutyl-3-(beta-maltosyl)-1-nitrosourea (TA-077). II. Hydrolysis by tissue homogenates and drug uptake by tumor cells in vitro.
Secretagogue response of azaserine-induced rat pancreatic acinar tumors in vivo.
Secretory, enzymatic, and morphological characterization of rat pancreatic endocrine tumours induced by streptozotocin and nicotinamide.
Structural development of synthetic retinoids and thalidomide-related molecules.
Sucrase-isomaltase expression and enterocytic ultrastructure of human colorectal tumors.
The alpha-glucosidase inhibitor miglitol suppresses postprandial hyperglycaemia and interleukin-1beta and tumour necrosis factor-alpha gene expression in rat peripheral leucocytes induced by intermittent sucrose loading.
Nephrosis, Lipoid
Fulminant pneumatosis intestinalis in a patient with diabetes mellitus and minimal change nephrotic syndrome.
Nephrotic Syndrome
Fulminant pneumatosis intestinalis in a patient with diabetes mellitus and minimal change nephrotic syndrome.
Nephrotic syndrome complicating alpha-glucosidase replacement therapy for Pompe disease.
Neuromuscular Diseases
Diagnosis of Pompe disease: muscle biopsy vs blood-based assays.
Non-alcoholic Fatty Liver Disease
alpha-Glucosidase inhibitor acarbose and sequestome 1/A170/p62 deficient mice: A promising therapy and unique model for non-alcoholic fatty liver disease.
Long-term combination therapy of ezetimibe and acarbose for non-alcoholic fatty liver disease.
Obesity
alpha-Glucosidase inhibition in obesity.
Alpha-glucosidase inhibitors 2012 - cardiovascular considerations and trial evaluation.
Inhibitory effects of estrogens on digestive enzymes, insulin deficiency, and pancreas toxicity in diabetic rats.
Macrophage foam cell formation is augmented in serum from patients with diabetic angiopathy.
Polyhydroxylated alkaloids isolated from mulberry trees (Morusalba L.) and silkworms (Bombyx mori L.).
Punica granatum flower extract, a potent alpha-glucosidase inhibitor, improves postprandial hyperglycemia in Zucker diabetic fatty rats.
The alpha-glucosidase inhibitor acarbose prevents obesity and simple steatosis in sequestosome 1/A170/p62 deficient mice.
The alpha-glucosidase inhibitor miglitol affects bile acid metabolism and ameliorates obesity and insulin resistance in diabetic mice.
The alpha-glucosidase inhibitor miglitol increases hepatic CYP7A1 activity in association with altered short-chain fatty acid production in the gut of obese diabetic mice.
[Drug clinics. How I treat various metabolic diseases treated by a drug intervention that targets the intestine]
[The effect of an alpha-glucosidase inhibitor on fatty liver in obesity]
Obesity, Abdominal
[Pharmacological treatment of postprandial hyperglycemia in hypertensive patients with type 2 diabetes mellitus]
oligo-1,6-glucosidase deficiency
Disaccharidase activity in male and female C57BL/6 mice infected with Giardia muris.
Prevalence of Disaccharidase Deficiency in Adults With Unexplained Gastrointestinal Symptoms.
Oligospermia
New discriminatory level for glucosidase activity to diagnose epididymal obstruction or dysfunction.
[The value of the level of alpha-1,4-glucosidase and seminal l-carnitine in patients with oligoasthenospermia]
Overweight
Clinical, endocrine, and metabolic effects of acarbose, a alpha-glucosidase inhibitor, in overweight and nonoverweight patients with polycystic ovarian syndrome.
Daily consumption of Reliv Glucaffect for 8 weeks significantly lowered blood glucose and body weight in 50 subjects.
Effects of the treatment with acarbose in elderly overweight type 2 diabetic patients in poor glycemic control with oral hypoglycemic agents or insulin.
The effects of the alpha-glucosidase inhibitor BAY g 5421 (Acarbose) on meal-stimulated elevations of circulating glucose, insulin, and triglyceride levels in man.
Pancreatic Diseases
Renal factors in serum trypsinogen 1 metabolism and excretion in chronic pancreatic disease.
Renal handling of amylase and immunoreactive trypsin in pancreatic cancer and chronic pancreatitis.
Pancreatic Neoplasms
Measurement of alpha-glucosidase activity in serum from patients with cystic fibrosis or pancreatitis.
Molecular size distribution of immunoreactive trypsin and renal tubular dysfunction: role in trypsin plasma-urine transfer.
Renal factors in serum trypsinogen 1 metabolism and excretion in chronic pancreatic disease.
Renal handling of amylase and immunoreactive trypsin in pancreatic cancer and chronic pancreatitis.
Renal tubular dysfunction in pancreatic cancer and chronic pancreatitis.
Pancreatitis
Measurement of alpha-glucosidase activity in serum from patients with cystic fibrosis or pancreatitis.
Serum beta-N-acetylglucosaminidase, beta-D-glucosidase, alpha-D-glucosidase, beta-D-fucosidase, alpha-L-fucosidase and beta-D-galactosidase levels in acute viral hepatitis, pancreatitis, myocardial infarction and breast cancer.
Pancreatitis, Chronic
Molecular size distribution of immunoreactive trypsin and renal tubular dysfunction: role in trypsin plasma-urine transfer.
Renal factors in serum trypsinogen 1 metabolism and excretion in chronic pancreatic disease.
Renal handling of amylase and immunoreactive trypsin in pancreatic cancer and chronic pancreatitis.
Renal tubular dysfunction in pancreatic cancer and chronic pancreatitis.
Paramyxoviridae Infections
Antiviral effects of glycosylation and glucose trimming inhibitors on human parainfluenza virus type 3.
Pelvic Inflammatory Disease
The influence of inflammation of the human male genital tract on secretion of the seminal markers alpha-glucosidase, glycerophosphocholine, carnitine, fructose and citric acid.
Periodontitis
Glycosidase activities in gingival crevicular fluid in subjects with adult periodontitis or gingivitis.
Peripheral Arterial Disease
Activity of cathepsin D and alpha-glucosidase in muscle from patients with peripheral arterial disease.
Plague
On the role of oligosaccharide trimming in the maturation of Sindbis and influenza virus.
Pneumatosis Cystoides Intestinalis
Correction to: Pneumatosis cystoides intestinalis induced by the alpha-glucosidase inhibitor complicated from sigmoid volvulus in a diabetic patient.
Pneumatosis cystoides intestinalis after alpha-glucosidase inhibitor treatment in a patient with interstitial pneumonitis.
Pneumatosis cystoides intestinalis after treatment with an alpha-glucosidase inhibitor.
Pneumatosis cystoides intestinalis following alpha-glucosidase inhibitor treatment: A case report and review of the literature.
Pneumatosis cystoides intestinalis in neuropsychiatric systemic lupus erythematosus with diabetes mellitus: case report and literature review.
Pneumatosis cystoides intestinalis induced by the alpha-glucosidase inhibitor complicated from sigmoid volvulus in a diabetic patient.
Pneumatosis cystoides intestinalis induced by the alpha-glucosidase inhibitor miglitol.
Pneumatosis cystoides intestinalis of the ascending colon related to acarbose treatment: a case report.
Regression of pneumatosis cystoides intestinalis after discontinuing of alpha-glucosidase inhibitor administration.
Pneumoperitoneum
A Rare Case of Benign Pneumatosis Intestinalis with Portal Venous Gas and Pneumoperitoneum Induced by Acarbose.
Polycystic Ovary Syndrome
Clinical, endocrine and metabolic effects of acarbose, an alpha-glucosidase inhibitor, in PCOS patients with increased insulin response and normal glucose tolerance.
Clinical, endocrine, and metabolic effects of acarbose, a alpha-glucosidase inhibitor, in overweight and nonoverweight patients with polycystic ovarian syndrome.
Porcine Reproductive and Respiratory Syndrome
The effect of porcine reproductive and respiratory syndrome virus and porcine epidemic diarrhea virus challenge on growing pigs II: Intestinal integrity and function.
Prediabetic State
Assessing the potential for alpha-glucosidase inhibitors in prediabetic states.
Premature Ejaculation
[Semen biochemical markers and their significance in the patients with premature ejaculation]
Prostatic Neoplasms
Potential risk of alpha-glucosidase inhibitor administration in prostate cancer external radiotherapy by exceptional rectal gas production: a case report.
Prostatitis
Evaluation of seminal plasma parameters in patients with chronic prostatitis or leukocytospermia.
Inflammatory-associated obstructions of the male reproductive tract.
The influence of inflammation of the human male genital tract on secretion of the seminal markers alpha-glucosidase, glycerophosphocholine, carnitine, fructose and citric acid.
Protein Deficiency
[Effect of protein deficiency in the female rat diet during pregnancy and lactation on the activity of the membrane and soluble forms of digestive enzymes in the offspring small intestine]
Protein-Energy Malnutrition
Effect of pre- & post-weaning protein energy malnutrition on intestinal sucrase & maltase in rats.
Moderate and severe protein energy malnutrition in childhood: effects on jejunal mucosal morphology and disaccharidase activities.
Proteinuria
[Diagnostic value of determining neutral alpha-glucosidase and N-acetyl-beta-D-hexosaminidase activity in the urine in kidney pathology]
[Modification of total and fractioned proteinuria and lysozyme, urine alpha-glucosidase and beta 2-microglobulin in a team of semiprofessional soccer players in 3 phases of the championship]
Psoriasis
Association between ?-glucosidase inhibitor use and psoriatic disease risk in patients with type 2 diabetes mellitus: A population-based cohort study.
Pyelonephritis
New sensitive markers for the detection of experimental ascending pyelonephritis.
[Neutral alpha glucosidase in human urine as a marker of kidney impairment]
Renal Insufficiency
[Alpha-glucosidase and alanine-amino-peptidase in the early diagnosis of renal failure in obstructive jaundice]
Renal Insufficiency, Chronic
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2016 EXECUTIVE SUMMARY.
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2017 EXECUTIVE SUMMARY.
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2018 EXECUTIVE SUMMARY.
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2019 EXECUTIVE SUMMARY.
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2020 EXECUTIVE SUMMARY.
Digestive-absorptive function of the intestinal brush border in uremia.
Respiratory Insufficiency
Lentiviral gene therapy of murine hematopoietic stem cells ameliorates the Pompe disease phenotype.
Phase I/II trial of adeno-associated virus-mediated alpha-glucosidase gene therapy to the diaphragm for chronic respiratory failure in Pompe disease: initial safety and ventilatory outcomes.
Rotavirus Infections
Differential tropism of EB rotavirus (serotype 3) to small intestine of homologous murine model.
Sleep Apnea, Obstructive
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2016 EXECUTIVE SUMMARY.
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2017 EXECUTIVE SUMMARY.
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2018 EXECUTIVE SUMMARY.
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2019 EXECUTIVE SUMMARY.
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2020 EXECUTIVE SUMMARY.
Starvation
Adaptive changes of intestinal enzymes to nutritional intake in the aging rat.
Dietary whey proteins and their peptides or amino acids: effects on the jejunal mucosa of starved rats.
Effect of starvation on small intestinal enzyme activity in germ-free rats.
Relationship between the changes in gastrin levels and intestinal properties in the starved rat.
[The influence of protein starvation on hydrolytic and transport characteristics of the rat small intestine in chronic experiments]
Stomach Neoplasms
Diabetes and risk of subsequent gastric cancer: a population-based cohort study in Taiwan.
sucrose alpha-glucosidase deficiency
The Role of Disaccharidase Deficiencies in Functional Abdominal Pain Disorders-A Narrative Review.
Uremia
Activities of intestinal enzymes in experimental chronic renal insufficiency.
Urinary Tract Infections
Diagnostic potential of urinary enzymes and beta 2-microglobulin in acute urinary tract infection.
Vaccinia
Recombinant HIV envelope expressed in an alpha-glucosidase I-deficient CHO cell line and its parental cell line in the presence of 1-deoxynojirimycin is functional.
Varicocele
Abnormal expression of acid glycosidases in seminal plasma and spermatozoa from infertile men with varicocele.
alpha-1,4-Glucosidase activity in infertile oligoasthenozoospermic men with and without varicocele.
Coiled sperm from infertile patients: characteristics, associated factors and biological implication.
Neutral alpha-1,4-glucosidase in human seminal plasma: molecular forms in varicocele and after vasectomy.
Origin of maltase and variations in infertile men.
[Effects of experimental varicocele on the apoptosis of epididymis epithelium and synthesizing function of the epididymis in rats]
Vascular Diseases
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2017 EXECUTIVE SUMMARY.
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2018 EXECUTIVE SUMMARY.
Ventricular Dysfunction, Left
N-methyl-1-deoxynojirimycin (MOR-14), an alpha-glucosidase inhibitor, markedly improves postischemic left ventricular dysfunction.
Virus Diseases
Role of membrane phospholipids and glycolipids in the Vero cell surface receptor for rubella virus.